var title_f35_2_35872="Irritated skin tag";
var content_f35_2_35872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irritated skin tag",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35872=[""].join("\n");
var outline_f35_2_35872=null;
var title_f35_2_35873="Mycosis fungoides plaque";
var content_f35_2_35873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycosis fungoides - plaque stage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous plaque with an annular configuration is present on the chest in this patient with plaque stage mycosis fungoides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35873=[""].join("\n");
var outline_f35_2_35873=null;
var title_f35_2_35874="Radiofrequency ablation of cord of acardiac twin";
var content_f35_2_35874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Radiofrequency ablation of cord of acardiac twin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image from a radiofrequency ablation of an acardiac twin. The probe (arrow) enters into the fetal anterior abdominal wall with the tines at the cord insertion site. The high signal around the tines (arrowhead) is due to gas formation during the procedure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35874=[""].join("\n");
var outline_f35_2_35874=null;
var title_f35_2_35875="The nephrotic syndrome";
var content_f35_2_35875=[" <h1 id=\"patTopicTitle\">",
"  Patient information: The nephrotic syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/2/35875/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35875/contributors\" id=\"au4305\">",
"       Ellie Kelepouris, MD, FAHA",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/2/35875/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35875/contributors\" id=\"se49\">",
"       Richard J Glassock, MD, MACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/2/35875/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35875/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/2/35875?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      NEPHROTIC SYNDROME OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The term nephrotic syndrome refers to a group of symptoms and laboratory findings that may occur in people with certain kinds of kidney (renal) disease.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       High levels of protein (albumin) in the urine",
"      </li>",
"      <li>",
"       Low levels of the protein (albumin) in the blood",
"      </li>",
"      <li>",
"       Swelling (also called edema) of the face, legs, or ankles due to the abnormal collection of fluids in the tissues, usually accompanied by weight gain",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This article will review the causes, evaluation, and treatment of nephrotic syndrome. More detailed information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"      \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW DOES NEPHROTIC SYNDROME DEVELOP?",
"     </span>",
"    </p>",
"    <p>",
"     Nephrotic syndrome develops when there is damage to the glomeruli, the structures in the kidneys that work to filter the blood (",
"     <a class=\"graphic graphic_figure graphicRef82497 \" href=\"mobipreview.htm?5/10/5286\">",
"      figure 1",
"     </a>",
"     ). This damage allows proteins in the blood (such as albumin) to leak into the urine, causing increased excretion of protein (proteinuria). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=see_link\">",
"      \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"     </a>",
"     .) Eventually, blood levels of albumin become reduced. Accompanying abnormalities of kidney function lead to accumulation of fluid in the tissues (edema).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      How are glomeruli damaged?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many different disorders can cause damage to the glomeruli, resulting in nephrotic syndrome. In some cases, damage is confined to the kidneys alone. In other cases, organs other than the kidney are also affected (such as in diabetes mellitus or systemic lupus erythematosus).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In children, the most common cause of glomerular damage is a condition known as minimal change disease.",
"      </li>",
"      <li>",
"       In adults, approximately 30 percent of people with nephrotic syndrome have an underlying medical problem, such as diabetes or lupus; the remaining cases are due to kidney disorders such as minimal change disease, focal segmental glomerulosclerosis, or membranous nephropathy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Minimal change disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Minimal change disease is a kidney disease that can occur in both adults and children. People with minimal change disease have normal or very mild abnormalities of the glomeruli. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"      \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Focal segmental glomerulosclerosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Focal segmental glomerulosclerosis (FSGS) is the most common cause of nephrotic syndrome in adults. FSGS causes collapse and scarring of some glomeruli. The cause of primary FSGS is unknown, although some cases (usually in children or young adults) are the result of a genetic defect, an infection, or a toxic response to a drug.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Membranous nephropathy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Membranous nephropathy is a condition in which the walls of the glomerular blood vessels become thickened from the accumulation of protein deposits, causing increased \"leakiness\". It is not clear why membranous nephropathy develops in most people, but an &ldquo;auto-immune&rdquo; mechanism is suspected (&ldquo;auto-immune&rdquo; = reaction to oneself). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"      \"Causes and diagnosis of membranous nephropathy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Diabetes mellitus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Kidney disease is common in people with diabetes who have chronically elevated blood glucose levels",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     high blood pressure. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"     </a>",
"     .) Some patients with more advanced disease can develop the nephrotic syndrome.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Lupus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lupus is a disease that can affect multiple organs of the body, including the kidney. Nephrotic syndrome is common in people with severe lupus. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"      \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      NEPHROTIC SYNDROME SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of nephrotic syndrome are swelling, weight gain, fatigue, blood clots, and infections. Kidney failure may develop in some people. Increased excretion of protein may lead to \"frothy\" appearing urine in the toilet bowel.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Swelling (edema)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Swelling that occurs in people with nephrotic syndrome commonly affects the lining of the eye socket, which often causes swelling around the eyes upon waking in the morning. Swelling (edema) can also occur in the feet or ankles after sitting or standing for any period of time. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"      \"Patient information: Edema (swelling) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Weight gain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Weight gain can occur in people who develop swelling. Weight gain can occur rapidly.",
"    </p>",
"    <p>",
"     Uncommonly, weight loss can occur in people who are losing large quantities of protein in the urine. This may be due to malnutrition or an underlying conditions, such as poorly controlled diabetes mellitus, a chronic viral infection, or cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Kidney failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people with nephrotic syndrome have a gradual decline in kidney function, which causes no symptoms in the early stages. However, as kidney function continues to worsen, symptoms of kidney failure can develop, including shortness of breath, weakness and easy fatigability (from anemia) and loss of appetite.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26304697\">",
"     <span class=\"h2\">",
"      Blood lipids",
"     </span>",
"     &nbsp;&mdash;&nbsp;The concentration of lipids (cholesterol",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     triglycerides) can become greatly elevated in nephrotic syndrome. If persistent, this may increase the risk of coronary artery disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Blood clots",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with nephrotic syndrome are at an increased risk of blood clots in the veins or arteries. Clots in the veins can travel to the lungs. This can be dangerous, or even fatal. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"      \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with severe nephrotic syndrome are at increased risk for infections (particularly children with minimal change disease), although the reasons for this are not well understood.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      NEPHROTIC SYNDROME DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Nephrotic syndrome is diagnosed based upon a number of laboratory tests, including urine and blood tests. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/14/30944?source=see_link\">",
"      \"Patient information: Renal (kidney) biopsy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Urine tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Urine tests are often done to determine the amount of protein in the urine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of blood tests may be recommended to help determine the underlying cause of nephrotic syndrome to assess the risk of complications and to evaluate overall kidney function. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H460668475#H460668475\">",
"      \"Differential diagnosis and evaluation of glomerular disease\", section on 'Patients with a nephrotic presentation'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Renal biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Renal (kidney) biopsy is the standard procedure for determining the underlying cause of nephrotic syndrome when a cause cannot be identified by noninvasive laboratory testing. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/14/30944?source=see_link\">",
"      \"Patient information: Renal (kidney) biopsy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      NEPHROTIC SYNDROME TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Treat the underlying disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first line of treatment in nephrotic syndrome is to treat the underlying cause, if the cause is found. In addition, almost all patients are given an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), which lower blood pressure, prevent worsening of kidney disease, and reduce the amount of protein excreted in the urine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Diabetes mellitus",
"     </span>",
"     &nbsp;&mdash;&nbsp;The optimal treatment for diabetic kidney disease is not well understood, although the best approach likely includes intensive management of blood sugar levels, cholesterol, and blood pressure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Lupus",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with lupus who have nephrotic syndrome or evidence of worsening kidney function can be treated with steroids and other medications that suppress the immune system. Most people respond well to such a regimen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Minimal change disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with minimal change disease almost always respond initially to treatment with glucocorticoids (steroids). However, relapses are common, and additional treatments are often required. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link\">",
"      \"Treatment of minimal change disease in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Focal segmental glomerulosclerosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prolonged treatment with glucocorticoids (steroids) is often recommended for people with primary focal segmental glomerulosclerosis (FSGS). Secondary FSGS is treated primarily with ACE inhibitors or ARBs (see",
"     <a class=\"local\" href=\"#H20\">",
"      'Treat the underlying disease'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Membranous nephropathy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The best treatment for membranous nephropathy is a source of debate. In many people, a period of \"watch and wait\" is recommended initially to determine if the condition is worsening or causing complications. During this time, an ACE inhibitor or ARB is recommended and it is important to keep blood pressure and cholesterol levels controlled. Additional treatment, including medications that suppress the immune system, may be needed if membranous nephropathy progresses.",
"    </p>",
"    <p>",
"     Without immunosuppressive treatment, approximately 10 to 30 percent of people with membranous nephropathy have a complete resolution of symptoms over several years; a further 10 to 30 percent of people have a partial remission; approximately 40 percent of people slowly lose renal function. As a result, most people with mild symptoms are advised to delay immunosuppressive treatment",
"     <span class=\"nowrap\">",
"      until/unless",
"     </span>",
"     symptoms worsen. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link\">",
"      \"Treatment of idiopathic membranous nephropathy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Treating the symptoms of nephrotic syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to treating the underlying cause of nephrotic syndrome, the signs and symptoms of nephrotic syndrome can sometimes be treated.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h3\">",
"      Proteinuria",
"     </span>",
"     &nbsp;&mdash;&nbsp;An ACE inhibitor or angiotensin receptor blocker (ARB) is often recommended to reduce the loss of protein in the urine (proteinuria). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"      \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h3\">",
"      Edema",
"     </span>",
"     &nbsp;&mdash;&nbsp;Swelling in the lower legs (edema) and collection of fluid in the abdomen (ascites) can occur in people with nephrotic syndrome. Edema and ascites often improve in people who follow a low sodium diet and take a \"water pill\" (diuretic). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"      \"Patient information: Low sodium diet (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"      \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h3\">",
"      High cholesterol",
"     </span>",
"     &nbsp;&mdash;&nbsp;High cholesterol levels are often seen in people with nephrotic syndrome. If nephrotic syndrome persists, treatment is needed to lower blood cholesterol. Most people are initially treated with a cholesterol-lowering medication called a statin. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"      \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h3\">",
"      Blood clots",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a blood clot forms in a blood vessel, treatment may include a blood thinner, such as warfarin (Coumadin), for as long as the nephrotic syndrome persists. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"      \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"      \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287436928\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395579\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/49/36626?source=see_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395605\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=see_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/14/30944?source=see_link\">",
"      Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18598?source=see_link\">",
"      Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link\">",
"      Treatment of minimal change disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Kidney Fund",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.akfinc.org/\">",
"      www.akfinc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Association of Kidney Patients",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aakp.org/\">",
"      www.aakp.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/2/35875/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/2/35875?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35875/abstract/1\">",
"      Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998; 338:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35875/abstract/2\">",
"      Wilmer WA, Hebert LA, Lewis EJ, et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999; 34:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35875/abstract/3\">",
"      Hovind P, Rossing P, Tarnow L, et al. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 2001; 60:277.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_2_35875=[""].join("\n");
var outline_f35_2_35875=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           NEPHROTIC SYNDROME OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW DOES NEPHROTIC SYNDROME DEVELOP?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           NEPHROTIC SYNDROME SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           NEPHROTIC SYNDROME DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           NEPHROTIC SYNDROME TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/10/5286\" title=\"figure 1\">",
"           Nephron anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_2_35876="Increased C1 to C2 spinous process distance";
var content_f35_2_35876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Increased C1 to C2 spinous process distance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) This figure demonstrates an example of an enlarged C1&ndash;2:C2&ndash;3 ratio (20:6) in a patient with tectorial membrane disruption as the bones would appear on lateral cervical spine radiograph or sagittal computed tomography cervical spine reconstruction.",
"    <br/>",
"    (B) Disrupted. The enlarged C1&ndash;2:C2&ndash;3 ratio in tectorial membrane disruption may be created by the vectors illustrated on this sagittal figure. The craniocervical junction is flexed in an supine young child on a flat surface (long curved arrow). Without an intact tectorial membrane firmly strapping the flexed cranium to C-2, the occipital condyles push down on the anterior rim of cup-shaped C-1 articulation (red arrow) and rotate the posterior ring of C-1 superiorly (straight black arrow). This enlarges the C1&ndash;2 interspace relative to the C2&ndash;3 interspace to create the abnormal C1&ndash;2:C2&ndash;3 ratio.",
"    <br/>",
"    (C) Normal. The entire Oc&mdash;C2 complex moves up as a unit with an intact tectorial membrane (solid black line). Movement of the occipital condyle is limited to rotation within the cup-shaped C-1 articulation (curved black arrow), and the joint relationship is maintained (straight black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35876=[""].join("\n");
var outline_f35_2_35876=null;
var title_f35_2_35877="Normal left hand x-ray";
var content_f35_2_35877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of normal left hand (AP, lateral, and oblique)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiographs of the left hand in the AP (A), lateral (B), and oblique (C) projections are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35877=[""].join("\n");
var outline_f35_2_35877=null;
var title_f35_2_35878="Chlorothiazide: Drug information";
var content_f35_2_35878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/62/21477?source=see_link\">",
"    see \"Chlorothiazide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/27/20919?source=see_link\">",
"    see \"Chlorothiazide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diuril&reg;;",
"     </li>",
"     <li>",
"      Sodium Diuril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diuril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer states that I.V. and oral dosing are equivalent. Some clinicians may use lower I.V. doses; however, because of chlorothiazide's poor oral absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 500-2000 mg daily divided in 1-2 doses (manufacturer labeling); doses of 125-500 mg daily have also been recommended (JNC 7)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Edema: Oral, I.V.: 500-1000 mg once or twice daily; intermittent treatment (eg, therapy on alternative days) may be appropriate for some patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      ACC/AHA 2009 Heart Failure guidelines:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 250-500 mg once or twice daily (maximum daily dose: 1000 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 500-1000 mg once or twice daily plus a loop diuretic",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/27/20919?source=see_link\">",
"      see \"Chlorothiazide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer states that I.V. and oral dosing are equivalent. Some clinicians may use lower I.V. doses; however, because of chlorothiazide's poor oral absorption. I.V. dosing in infants and children has not been well established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Infants &lt;6 months:",
"     </i>",
"     Oral: 10-30 mg/kg/day in 2 divided doses (maximum dose: 375 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Infants &gt;6 months and Children:",
"     </i>",
"     Oral: 10-20 mg/kg/day in 1-2 divided doses (maximum dose: 375 mg daily in children &lt;2 years or 1000 mg daily in children 2-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Infants and Children: I.V. (unlabeled):",
"     </i>",
"     5-10 mg/kg/day in 2 divided doses (Costello, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F149887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use. Ineffective with  Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute unless in combination with a loop diuretic (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2009 Heart Failure Guidelines suggest that thiazides lose their efficacy when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sodium Diuril&reg;: 0.5 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diuril&reg;: 250 mg/5 mL (237 mL) [contains benzoic acid, ethanol 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do",
"     <b>",
"      not",
"     </b>",
"     administer injection via I.M. or SubQ route. Administer slowly by direct I.V. injection or infusion; avoid extravasation of parenteral solution since it is extremely irritating to tissues.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F149918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alprostadil.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension; adjunctive treatment of edema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3196858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diuril [U.S., Canada] may be confused with Duorol brand name for acetaminophen [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, orthostatic hypotension, necrotizing angiitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, restlessness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme, exfoliative dermatitis, photosensitivity, purpura, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased, hypercalcemia, hyperglycemia, hyperuricemia, hypochloremic alkalosis, hypokalemia, hyponatremia, hypomagnesemia, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramping, anorexia, constipation, diarrhea, gastric irritation, nausea, pancreatitis, sialadenitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, xanthopsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glycosuria, hematuria (I.V.), interstitial nephritis, renal failure, renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pneumonitis, pulmonary edema, respiratory distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reactions, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorothiazide, any component of the formulation or sulfonamide-derived drugs; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypercalcemia, hypokalemia, hypochloremic alkalosis, hyponatremia, and hypomagnesemia can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with a sulfonamide allergy is specifically contraindicated in product labeling. A risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid in severe renal disease (ineffective). May precipitate azotemia; discontinue or consider withholding if renal impairment occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F149876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase risk of orthostatic hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Chlorothiazide serum levels may be increased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may worsen hypertension). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies; however, studies were not complete. Chlorothiazide crosses the placenta and is found in cord blood. Maternal use may cause may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults. Use of thiazide diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F149865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May need to decrease sodium and calcium, may need to increase potassium, zinc, magnesium, and riboflavin in diet. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F149862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Chlorothiazide Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $348.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Sodium Diuril Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $519.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Diuril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (237 mL): $63.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $13.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $25.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F149851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, renal function, blood pressure; assess weight, I &amp; O reports daily to determine fluid loss",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azide (AU);",
"     </li>",
"     <li>",
"      Chlorosal (IL);",
"     </li>",
"     <li>",
"      Chlotride (AU, NL);",
"     </li>",
"     <li>",
"      Disalunil (PL);",
"     </li>",
"     <li>",
"      Diurilix (FR);",
"     </li>",
"     <li>",
"      Diurone (AU);",
"     </li>",
"     <li>",
"      Diurosulfona (ES);",
"     </li>",
"     <li>",
"      Hydrochlorothiazidum (PL);",
"     </li>",
"     <li>",
"      Niagar (BE);",
"     </li>",
"     <li>",
"      Saluretil (ES);",
"     </li>",
"     <li>",
"      Saluric (GB, IE);",
"     </li>",
"     <li>",
"      Salutrid (FI);",
"     </li>",
"     <li>",
"      Urinex (FI)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium and chloride reabsorption in the distal tubules causing increased excretion of sodium, chloride, and water resulting in diuresis. Loss of potassium, hydrogen ions, magnesium, phosphate, and bicarbonate also occurs.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: Oral: Within 2 hours; I.V.: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Oral: ~4 hours; I.V.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of diuretic action: Oral: ~6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 45-120 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (10% to 15% [oral], 96% [I.V.] as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/2/35878/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/2/35878/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff G, Brier M, Berns J, et al,",
"      <i>",
"       The Renal Drug Book",
"      </i>",
"      , online edition, 2002. Available at",
"      <a href=\"file://www.kdp-baptist.louisville.edu/renalbook\" target=\"_blank\">",
"       file://www.kdp-baptist.louisville.edu/renalbook",
"      </a>",
"      . Last accessed September 20, 2005.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/2/35878/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Costello JM and Almodovar MC, \"Emergency Care for Infants and Children With Acute Cardiac Disease,\"",
"      <i>",
"       Clin Pediatr Emerg Med",
"      </i>",
"      , 2007, 8(3):145-55.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/2/35878/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/2/35878/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/2/35878/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Werthmann MW Jr and Krees SV, \"Excretion of Chlorothiazide in Human Breast Milk,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1972, 81(4):781-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/2/35878/abstract-text/5074355/pubmed\" id=\"5074355\" target=\"_blank\">",
"        5074355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9248 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35878=[""].join("\n");
var outline_f35_2_35878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149881\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149882\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149912\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149885\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149902\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149886\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149887\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682602\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149853\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149836\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149857\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149918\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149856\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3196858\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149910\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149860\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149840\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299022\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149845\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149876\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149848\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149863\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149891\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149865\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149862\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149851\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038559\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149839\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149859\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9248|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/62/21477?source=related_link\">",
"      Chlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/27/20919?source=related_link\">",
"      Chlorothiazide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_2_35879="Medication overuse headache: Etiology, clinical features, and diagnosis";
var content_f35_2_35879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medication overuse headache: Etiology, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35879/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35879/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35879/contributors\">",
"     Todd J Schwedt, MD, MSCI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35879/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35879/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35879/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35879/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/2/35879/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily headache is a descriptive term that encompasses several different specific headache diagnoses. Chronic daily headache types of long duration (ie, four hours or more) include chronic migraine, chronic tension-type headache, medication overuse headache, hemicrania continua, and new daily persistent headache. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the etiology, clinical features, and diagnosis of medication overuse headache (MOH). Treatment and prognosis of MOH and other subtypes of chronic daily headache are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/48/17161?source=see_link\">",
"     \"Medication overuse headache: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication overuse headache (MOH) has also been termed analgesic rebound headache, drug-induced headache, and medication-misuse headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/1\">",
"     1",
"    </a>",
"    ]. Although not a primary type of chronic daily headache, MOH deserves proper coverage since it frequently coexists with primary chronic daily headache. Furthermore, the presence of MOH can preclude the successful treatment of the underlying primary headache disorder, most often migraine or tension-type headache. In some cases, MOH may be associated with the development or maintenance of a chronic daily headache syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/2\">",
"     2",
"    </a>",
"    ]. After successful MOH treatment, preventive medications for the underlying primary headache disorder have a greater chance for success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available evidence suggests all drugs used for the acute symptomatic treatment of headache can cause MOH in primary headache disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The precise mechanisms that lead to MOH are still uncertain. However, multiple factors seem to play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various studies and clinical observations suggest that MOH is restricted to individuals who already have other headache disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, MOH does not develop de novo in individuals with no previous headache history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 103 patients using daily analgesics for arthritic pain but not for headache, only eight patients (7.6 percent) had chronic daily headache, each of whom reported a previous history of episodic migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/7\">",
"     7",
"    </a>",
"    ]. This study supports the hypothesis that patients with previous episodic headaches may be susceptible to developing MOH and that analgesics may merely be a cofactor to the development of chronic daily headache in a genetically vulnerable individual.",
"   </p>",
"   <p>",
"    Patients with migraine and tension-type headache seem to have the highest potential for MOH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/8\">",
"     8",
"    </a>",
"    ]. However, MOH has also been described in cluster headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/9\">",
"     9",
"    </a>",
"    ] and in hemicrania continua [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Central sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigations demonstrating facilitation of trigeminal pain processing in patients with chronic headache have suggested that central sensitization, the same process that occurs in migraine, can lead to MOH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/5,8,11\">",
"     5,8,11",
"    </a>",
"    ]. Daily exposure to some triptans can downregulate serotonin receptor subtypes 5-HT 1B and 5-HT 1D, and influence serotonin synthesis in the rat central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, chronic exposure to triptans and other analgesics could lead to downregulation of serotonin receptors and changes in central inhibitory pathways that translate to an impairment of antinociceptive activity and a permanent feeling of head pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4\">",
"     4",
"    </a>",
"    ]. In support of this argument, neurophysiologic studies have shown facilitation of trigeminal and somatic nociceptive systems in MOH primarily mediated at a supraspinal level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/13\">",
"     13",
"    </a>",
"    ]. Another study in rats found that sustained or repeated triptan treatment induced pro-nociceptive neural adaptations and enhanced responses to nitric oxide, a known trigger of migraine headache in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, a report that measured glucose metabolism in migraineurs with MOH using 18-F-fluorodeoxyglucose positron emission tomography (FDG-PET) demonstrated reversible metabolic change in pain processing structures and persistent orbitofrontal hypofunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to opiates also causes changes in the nervous system. Peripherally, the chronic administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    results in increased expression of calcitonin gene-related peptide in primary afferent neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/16\">",
"     16",
"    </a>",
"    ]. Centrally, prolonged exposure to this opiate leads to increased descending facilitation from the rostral ventromedial medulla and increased excitatory neurotransmission at the level of the dorsal horn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/16\">",
"     16",
"    </a>",
"    ]. The combination of these may result in MOH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Biobehavioral factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that MOH is a biobehavioral disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/17\">",
"     17",
"    </a>",
"    ]. Some patients may have addictive disease, characterized by compulsive drug seeking and drug taking behavior despite negative consequences, as the basis of MOH. Other patients may use opiates or other drugs with",
"    <span class=\"nowrap\">",
"     sedative/anxiolytic",
"    </span>",
"    effects to treat both pain and a coexistent anxiety disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behaviors that may be particularly important in prompting and sustaining the overuse of medication include fear of headache, anticipatory anxiety, obsessional drug-taking behavior, and psychologic drug dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/17\">",
"     17",
"    </a>",
"    ]. In a prospective population-based longitudinal study of 32,067 adults from Norway, subjects using analgesics daily or weekly at baseline had a significantly increased risk of chronic pain 11 years later compared with those who never used analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/18\">",
"     18",
"    </a>",
"    ]. Subjects with chronic migraine had the highest risk (relative risk 13.3, 95% CI 9.3-19.1).",
"   </p>",
"   <p>",
"    Further evidence that MOH is part of the spectrum of addictive disorders comes from the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-control study, patients with MOH derived from migraine (n = 41) had a significantly greater risk of substance-related disorders than those with episodic migraine (n = 41) (odds ratio 7.6, 95% CI 2.2-26) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 1861 patients with chronic daily headache, 895 met criteria for probable MOH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/20\">",
"       20",
"      </a>",
"      ]. Substance dependence as diagnosed by DSM-IV criteria was significantly more frequent in patients with MOH than those without MOH (68 versus 20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of MOH in the general population is approximately 1 percent, and is higher in women than in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/5,11,21\">",
"     5,11,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of over 49,000 subjects from Norway, the prevalence of chronic headache with analgesic overuse lasting three months or longer was 0.9 percent overall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/22\">",
"       22",
"      </a>",
"      ]. For women and men, the prevalence was 1.2 and 0.6 percent, respectively.",
"     </li>",
"     <li>",
"      In two smaller population studies from Spain, the prevalence of medication overuse headache was approximately 1.5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/21,23\">",
"       21,23",
"      </a>",
"      ], with a female to male ratio of 17:1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients who are seen at specialized headache centers, the prevalence of MOH is much higher, ranging from 4 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4,24,25\">",
"     4,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Migraine is the most common primary headache disorder associated with MOH. In a meta-analysis of 29 studies that included a total of 2612 patients with chronic MOH, the underlying primary headache type was migraine, tension-type, or",
"    <span class=\"nowrap\">",
"     mixed/other",
"    </span>",
"    in 65, 27, and 8 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to medication overuse, anxiety and depression may be risk factors for the evolution of migraine into MOH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Biobehavioral factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A low socioeconomic status may be another risk factor for the development of MOH in migraineurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Causal medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;All acute symptomatic medications used to treat headaches have the potential for causing MOH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the degree of risk differs depending upon the specific medication or class of medications. Based upon the literature and clinical experience, the risk appears to be highest with opioids, butalbital-containing combination analgesics, and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"      aspirin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"      acetaminophen",
"     </a>",
"     /caffeine",
"    </span>",
"    combinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/11\">",
"     11",
"    </a>",
"    ]. The risk for MOH with triptans is considered intermediate by some experts but high by others. The risk is lowest with nonsteroidal antiinflammatory drugs (NSAIDS).",
"   </p>",
"   <p>",
"    The evidence supporting these risks is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A longitudinal population-based study that included 8219 subjects with episodic migraine (from a population sample of 120,000) showed that any use of barbiturates or opiates is associated with an increased risk of transformation from episodic to chronic migraine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2008 review of clinic-based and population studies found that, for opiates, the increased risk was more pronounced in men, and the critical dose of exposure was approximately eight days a month [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. For barbiturates, the critical dose of exposure was approximately five days a month and the effect appeared greater in women. Triptans and NSAIDs induced migraine transformation only in those with a migraine frequency of 10 to 14 days per month.",
"     </li>",
"     <li>",
"      In a 2004 report from a tertiary headache center in New York of 169 patients who were followed in the last five years of the study (ie, the triptan era), the drugs most often associated with MOH included the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/2\">",
"       2",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Butalbital containing combination products, 48 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      , 46 percent",
"     </li>",
"     <li>",
"      Opioids, 33 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      32 percent",
"     </li>",
"     <li>",
"      Triptans, 18 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"       Ergotamine",
"      </a>",
"      tartrate, 12 percent",
"     </li>",
"     <li>",
"      NSAIDS other than ASA, 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2002 prospective German study of 98 patients with MOH, including 70 patients with migraine as the underlying primary headache type, overuse of triptans led to MOH sooner than overuse of ergots or analgesics, and did so at a lower frequency of use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/30\">",
"       30",
"      </a>",
"      ]. The mean interval until onset of MOH was shortest for triptans (1.7 years), longer for ergots (2.7 years), and longest for analgesics (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      , barbiturates, caffeine combinations) (4.8 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/30\">",
"       30",
"      </a>",
"      ]. Similarly, the mean critical monthly intake frequency for MOH was lowest for triptans (18 single doses per month), higher for ergots (37 single doses per month), and highest for analgesics (114 single doses per month). However, the study was not designed to stratify risk among different substances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of use for drugs implicated in MOH varies from country to country and is influenced by multiple factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4\">",
"     4",
"    </a>",
"    ], including the introduction of new acute headache medications over time. Butalbital is commonly overused in the United States, while simple analgesics and caffeine-containing drugs are most commonly associated with MOH in other parts of the world (eg, Spain and Brazil) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/21,31\">",
"     21,31",
"    </a>",
"    ]. Until the mid 1990s, combination analgesics with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    or caffeine, or ergots combined with caffeine were the most frequently overused drugs associated with MOH in many European countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the introduction of triptans, the pattern of MOH may be changing. In a review of patients seen at a single headache center in the US from 1990 to 2005, MOH secondary to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    decreased while MOH secondary to triptans increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is often difficult to identify a single causal substance for MOH, since many patients are overusing more than one drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. In the Brazilian study of 133 patients with transformed migraine and symptomatic medication overuse, the frequencies of patients overusing one, two, or three medication categories were 55, 41, and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of MOH is typically preceded by an episodic headache disorder, typically migraine or tension-type headache, that has been treated with frequent and excessive amounts of acute symptomatic medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/11\">",
"     11",
"    </a>",
"    ]. In clinical practice, MOH often manifests as a headache that is present or develops upon awakening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/11\">",
"     11",
"    </a>",
"    ]. Acute symptomatic treatment only provides transient relief, which leads to more acute symptomatic medication use.",
"   </p>",
"   <p>",
"    The severity, location, and type of head pain with MOH can vary significantly among different individuals, but headache commonly occurs daily or nearly daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/11\">",
"     11",
"    </a>",
"    ]. Nausea, asthenia, difficulty concentrating, memory problems, and irritability can accompany MOH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To some extent, the clinical features of MOH may depend upon the type of headache medication that is overused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/30\">",
"     30",
"    </a>",
"    ]. In a prospective study of 98 patients with MOH, which included a majority of patients (71 percent) having migraine as the underlying type of headache, patients overusing ergots and analgesics (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , barbiturates, caffeine combinations) typically had a daily tension-type headache, while those with triptan-induced MOH were more likely to describe a daily migraine-like headache or an increase in migraine frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MOH is based upon clinical impression. The course of the headache disorder and the history of drug intake and intake frequency are the only available methods of diagnosis. A history of analgesic use averaging more than two to three days per week in association with chronic daily headache supports the diagnosis of MOH. The diagnosis is made when there is a pattern of frequent headaches that fulfill diagnostic criteria for MOH listed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other disorders causing secondary headache must be excluded. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In practice, some patients may be reluctant to fully disclose their drug history, particularly with regard to the frequency and amount consumed. In addition, it is not uncommon for patients to report prescription medications but not over-the-counter analgesics. In order to improve the accuracy of the drug history, it may be helpful to explain the concept of MOH to the patient, including the critical importance of medication use to development, diagnosis, and treatment of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Classification of Headache Disorders 2nd edition (ICHD 2) diagnostic criteria for MOH were published in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/1\">",
"     1",
"    </a>",
"    ] and revised in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/33\">",
"     33",
"    </a>",
"    ]. The revised criteria for MOH are as follows (",
"    <a class=\"graphic graphic_table graphicRef71798 \" href=\"mobipreview.htm?8/35/8763\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache present on &ge;15 days a month",
"     </li>",
"     <li>",
"      Regular overuse for more than three months of one or more",
"      <span class=\"nowrap\">",
"       acute/symptomatic",
"      </span>",
"      treatment drugs:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"       Ergotamine",
"      </a>",
"      , triptans, opioids, OR combination analgesic medications on &ge;10 days a month on a regular basis for more than three months",
"     </li>",
"     <li>",
"      Simple analgesics OR any combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      , triptans, analgesic opioids on &ge;15 days a month on a regular basis for more than three months without overuse of any single class alone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache has developed or markedly worsened during medication overuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Note that \"overuse\" is defined by the frequency of medication treatment, and the criteria for overuse are specific for the type of medication being overused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any form of chronic daily headache, whether primary or secondary, needs to be considered in the differential diagnosis of MOH. Primary headache subtypes of chronic daily headache include chronic migraine, chronic tension-type headache, hemicrania continua, and new daily persistent headache. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=see_link\">",
"     \"Chronic migraine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43942?source=see_link\">",
"     \"Hemicrania continua\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2968?source=see_link\">",
"     \"New daily persistent headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other primary headache disorders, however, can also present as a chronic daily headache. The list includes cluster headache, SUNCT, hypnic headache, nummular headache, and chronic paroxysmal hemicrania. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5700?source=see_link\">",
"     \"Hypnic headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate diagnostic testing should be undertaken if clinical evaluation indicates the possibility of a serious medical or neurologic condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=see_link\">",
"     \"Evaluation of the adult with headache in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A high frequency of drug intake does not mean that MOH is the only headache disorder that is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4\">",
"     4",
"    </a>",
"    ]. Typically, the patient with MOH has an underlying primary headache disorder (eg, migraine, tension-type headache) that gradually or abruptly increased in frequency, which in turn led to an increased intake of analgesics and eventually to MOH superimposed upon the primary headache disorder. At this stage, patients may find themselves taking daily or frequent analgesics merely to prevent a disabling analgesic withdrawal headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       \"Patient information: Headache (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medication overuse headache (MOH) was previously termed analgesic rebound headache, drug-induced headache, and medication-misuse headache. MOH is not a primary headache but frequently coexists with primary chronic daily headache. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The precise mechanisms that lead to MOH are still uncertain. However, multiple factors seem to play a role. These include (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Genetic predisposition",
"     </li>",
"     <li>",
"      Central sensitization of trigeminal pain processing",
"     </li>",
"     <li>",
"      Biobehavioral factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of MOH in the general population is approximately 1 percent, and is higher in women than in men. Migraine is the most common primary headache disorder associated with MOH. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All acute symptomatic medications used to treat headaches have the potential for causing MOH. The risk for MOH appears to vary as follows (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Causal medications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Highest with opioids, butalbital-containing combination analgesics, and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"        aspirin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"        acetaminophen",
"       </a>",
"       /caffeine",
"      </span>",
"      combinations",
"     </li>",
"     <li>",
"      Intermediate to high with triptans",
"     </li>",
"     <li>",
"      Lowest with nonsteroidal antiinflammatory drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of MOH is typically preceded by an episodic headache disorder, usually migraine or tension-type headache, that has been treated with frequent and excessive amounts of acute symptomatic medications. MOH often manifests as a headache that is present or develops upon awakening, and commonly occurs daily or nearly daily. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of MOH is based upon clinical impression. A history of analgesic use averaging more than two to three days per week in association with chronic daily headache is suggestive. The diagnosis is made when the pattern of frequent headaches fulfills the diagnostic criteria for MOH (",
"      <a class=\"graphic graphic_table graphicRef71798 \" href=\"mobipreview.htm?8/35/8763\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/2\">",
"      Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. Cephalalgia 2004; 24:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/3\">",
"      Mathew NT, Kurman R, Perez F. Drug induced refractory headache--clinical features and management. Headache 1990; 30:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/4\">",
"      Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/5\">",
"      Abrams BM. Medication overuse headaches. Med Clin North Am 2013; 97:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/6\">",
"      Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headaches de novo? Headache 1988; 28:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/7\">",
"      Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003; 43:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/8\">",
"      Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol 2007; 20:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/9\">",
"      Paemeleire K, Bahra A, Evers S, et al. Medication-overuse headache in patients with cluster headache. Neurology 2006; 67:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/10\">",
"      Young WB, Silberstein SD. Hemicrania continua and symptomatic medication overuse. Headache 1993; 33:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/11\">",
"      Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache 2006; 46 Suppl 4:S202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/12\">",
"      Dobson CF, Tohyama Y, Diksic M, Hamel E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 2004; 24:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/13\">",
"      Ayzenberg I, Obermann M, Nyhuis P, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006; 26:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/14\">",
"      De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 2010; 67:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/15\">",
"      Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006; 129:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/16\">",
"      Boes CJ, Black DF, Dodick DW. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 2006; 26:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/17\">",
"      Saper JR, Hamel RL, Lake AE 3rd. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia 2005; 25:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/18\">",
"      Zwart JA, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003; 61:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/19\">",
"      Radat F, Creac'h C, Swendsen JD, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005; 25:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/20\">",
"      Fuh JL, Wang SJ, Lu SR, Juang KD. Does medication overuse headache represent a behavior of dependence? Pain 2005; 119:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/21\">",
"      Pascual J, Col&aacute;s R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep 2001; 5:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/22\">",
"      Zwart JA, Dyb G, Hagen K, et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 2004; 62:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/23\">",
"      Castillo J, Mu&ntilde;oz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999; 39:190.",
"     </a>",
"    </li>",
"    <li>",
"     Diener, HC, Limmroth,V, Katsarava, Z. Medication-Overuse Headache. In: Chronic daily headache for clinicians, Goadsby, PJ, Dodick, DW (Eds) Decker, Hamilton, Ontario 2005. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/25\">",
"      Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother 2007; 7:1145.",
"     </a>",
"    </li>",
"    <li>",
"     Diener HC, Dahlof CG. Headache associated with chronic use of substances. In: The Headaches, Second ed, Olesen J, Tfelt-Hansen P, Welch KM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.871.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/27\">",
"      Atasoy HT, Unal AE, Atasoy N, et al. Low income and education levels may cause medication overuse and chronicity in migraine patients. Headache 2005; 45:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/28\">",
"      Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/29\">",
"      Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008; 71:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/30\">",
"      Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/31\">",
"      Krymchantowski AV. Overuse of symptomatic medications among chronic (transformed) migraine patients: profile of drug consumption. Arq Neuropsiquiatr 2003; 61:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/32\">",
"      Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006; 46:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35879/abstract/33\">",
"      Headache Classification Committee, Olesen J, Bousser MG, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26:742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3340 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35879=[""].join("\n");
var outline_f35_2_35879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Central sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Biobehavioral factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Causal medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3340|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/35/8763\" title=\"table 1\">",
"      Medication overuse headache criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=related_link\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=related_link\">",
"      Evaluation of the adult with headache in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43942?source=related_link\">",
"      Hemicrania continua",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5700?source=related_link\">",
"      Hypnic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/48/17161?source=related_link\">",
"      Medication overuse headache: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2968?source=related_link\">",
"      New daily persistent headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16243?source=related_link\">",
"      Nummular headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37830?source=related_link\">",
"      Overview of chronic daily headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_2_35880="Outpatient management of oral anticoagulation";
var content_f35_2_35880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Outpatient management of oral anticoagulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35880/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35880/contributors\">",
"     Karen A Valentine, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35880/contributors\">",
"     Russell D Hull, MBBS, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35880/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35880/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/2/35880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of options are available for the outpatient management of anticoagulation with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonists. These include supervision by hospital-based or community-based physicians, anticoagulation clinics, and self-monitoring and self-management programs. This subject, along with the importance of strict INR control, will be discussed here.",
"   </p>",
"   <p>",
"    The clinical uses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , warfarin use in the elderly, correction of excess anticoagulation, and a patient information sheet for the use of oral anticoagulants are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link\">",
"     \"Anticoagulation in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"     \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision regarding which anticoagulant to use for a specific indication is discussed in the topic on the indication in question. General issues related to the use of other anticoagulants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELATIVE EFFICACY OF DIFFERENT MANAGEMENT PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No matter how the management of oral anticoagulation is accomplished, patients still spend a considerable proportion of time with their targeted degree of anticoagulation",
"    <strong>",
"     outside",
"    </strong>",
"    of the recommended INR range. This issue was addressed in a meta-analysis of 67 studies involving 50,208 patients followed for a total of 57,155 patient-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/1\">",
"     1",
"    </a>",
"    ]. The INR was in the therapeutic range an average of 64 percent of the time, and the rate varied with study setting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Self-management &mdash; 72 percent",
"     </li>",
"     <li>",
"      Randomized trials &mdash; 66 percent",
"     </li>",
"     <li>",
"      Anticoagulation clinics &mdash; 66 percent",
"     </li>",
"     <li>",
"      Community physicians &mdash; 57 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Self-management, which yielded the highest percent of time spent within the therapeutic INR range, is not feasible for all patients, and requires identification and education of suitable candidates as well as an underlying institutional policy for providers of this service. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Self-monitoring and self-management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The importance of better anticoagulation control is discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Importance of strict INR control'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION CLINICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have shown that management of anticoagulation by hospital-based anticoagulation clinics is at least as good as routine hospital follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/3\">",
"     3",
"    </a>",
"    ], and marginally better than management directed by family physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/4\">",
"     4",
"    </a>",
"    ]. However, neither study was designed to evaluate possible differences in long-term outcome or cost-effectiveness.",
"   </p>",
"   <p>",
"    A randomized multicenter trial tested the efficacy and safety of management of anticoagulation using either a new version of the PARMA 5 computer program or manual dosage change by experienced medical staff at centers with a known interest in oral anticoagulation. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall success in achieving \"time in target INR range\" was 65 and 66 percent for the manual and computer-assisted programs, respectively.",
"     </li>",
"     <li>",
"      The total number of adverse events was lower in the group using the computer-assisted program (5.5 versus 6.0 events per 100 patient-years), but this difference was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The annual cost of a decentralized outpatient pharmacy service for regulating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy in a managed care setting has been estimated at approximately 600 United States dollars per year per person [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/6\">",
"     6",
"    </a>",
"    ]. This estimate included clinical pharmacy specialist costs, direct and indirect costs of INR testing, drug costs, and dispensing fees. A systematic review and meta-analysis compared the effects of participation by a pharmacist versus usual care on warfarin therapy outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/7\">",
"     7",
"    </a>",
"    ]. Pharmacist-participated warfarin therapy management (PWTM) was associated with a significantly reduced incidence of total bleeding (RR 0.51; 95% CI 0.28-0.94). However, the effects of PWTM on major bleeding, thromboembolic events, all-cause mortality, and warfarin-related mortality were not significantly different.",
"   </p>",
"   <p>",
"    A retrospective observational cohort design was used to investigate anticoagulation clinic patients who were managed either by telephone encounters or during face-to-face clinic encounters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/8\">",
"     8",
"    </a>",
"    ]. There were no significant differences in INR control, episodes or bleeding or thrombosis, emergency department visits, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -related hospital admissions between the two groups.",
"   </p>",
"   <p>",
"    While anticoagulation clinics may use computerized decision support systems in an effort to improve anticoagulation control, monitoring patients and assuring the appropriate frequency of follow-up testing is still labor intensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Regardless of the management system employed, assuring that the patient is adequately educated about the risks of treatment with oral anticoagulants is critical. This was shown in a study of 2346",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -treated adults in whom there were 126 hospitalizations due to warfarin-related bleeding over a two-year follow-up period. The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who reported receiving medication instructions from either a physician or nurse plus a pharmacist had a 60 percent reduced rate of subsequently experiencing a serious bleeding event over the next two years (adjusted risk ratio 0.40; 95% CI 0.24-0.68). Patients reported that receiving these instructions made it clear what to do if a dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was missed as well as what drugs to avoid while taking warfarin.",
"     </li>",
"     <li>",
"      Having &ge;4 physicians providing medication prescriptions over the last three months and filling prescriptions at &gt;1 pharmacy over the last three months were independently associated with increased bleeding rates (adjusted risk ratio 2.4; 95% CI 1.2-4.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22917624\">",
"    <span class=\"h2\">",
"     Cost effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three studies have shown the cost effectiveness of an anticoagulation",
"    <span class=\"nowrap\">",
"     service/clinic",
"    </span>",
"    because of a reduced number of emergency department visits and hospitalizations for anticoagulation-related hemorrhage or thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. When the costs of personnel required to staff the",
"    <span class=\"nowrap\">",
"     service/clinic",
"    </span>",
"    were factored in, the estimated savings, when compared with routine medical care, varied from 861 to 2414 US dollars per patient per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SELF-MONITORING AND SELF-MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small portable devices are available that enable patients to measure their own degree of anticoagulation (ie, in home measurement of their INR) with varying degrees of accuracy. When accompanied by appropriate education and training along with consistent quality control, the majority of patients, including the elderly, can effectively and safely adjust their own anticoagulant dosing (",
"    <a class=\"graphic graphic_figure graphicRef52321 \" href=\"mobipreview.htm?31/42/32429\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Limitations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two of the largest trials comparing self-management with standard care (ie, monitoring by a private physician or anticoagulation clinic) and three metaanalysis are reviewed below.",
"   </p>",
"   <p>",
"    In the largest trial (",
"    <strong>",
"     T",
"    </strong>",
"    he",
"    <strong>",
"     H",
"    </strong>",
"    ome",
"    <strong>",
"     INR",
"    </strong>",
"    <strong>",
"     S",
"    </strong>",
"    tudy [THINRS]), 2922 patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    because of the presence of a mechanical heart valve or atrial fibrillation, and who were judged competent in the use of point-of-care INR devices, were randomly assigned to either weekly self-testing at home or monthly high-quality clinic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/23\">",
"     23",
"    </a>",
"    ]. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After a total of 8730 patient-years of follow-up, the time to the first primary event (stroke, major bleeding episode, or death) was not significantly longer in the self-testing group than in the clinic-testing group (HR 0.88; 95% CI 0.75-1.04).",
"     </li>",
"     <li>",
"      The two groups had similar rates of clinical outcomes, although the self-testing group reported more minor bleeding episodes",
"     </li>",
"     <li>",
"      Over the entire follow-up period, the self-testing group had a small but significant improvement in the percent of time during which the INR was within the target range (absolute difference: 3.8 percentage points), as well as small but significant improvements in patient satisfaction and quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second trial, 737 patients receiving oral anticoagulation at a university-affiliated hospital were randomly assigned to receive conventional management in an anticoagulation clinic or self-management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/24\">",
"     24",
"    </a>",
"    ]. Final participation in the self-management arm was only 78 percent compared with 98 percent in the conventional treatment arm due to patient preferences both before and after they had received training in self-management techniques. On an intent-to-treat analysis, the following results were noted at a median follow-up of 12 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of control of the INR (ie, percent of time within the target range) was similar in the conventional and self-management treatment arms (65 versus 64 percent, respectively)",
"     </li>",
"     <li>",
"      The rates of major complications (ie, severe hemorrhage and thrombotic complications; 7.3 versus 2.2 percent), minor hemorrhage (36 versus 15 percent), and death (4.1 versus 1.6 percent) were all significantly higher in the conventional treatment arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five meta-analyses of randomized trials have concluded that appropriately trained patients who self-adjusted",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    self-monitored their oral anticoagulation had fewer thromboembolic events and no increase in episodes of major bleeding; most have also indicated a lower mortality compared with those undergoing standard monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/25-29\">",
"     25-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-monitoring is not feasible for all patients, and requires identification and education of suitable candidates as well as an underlying institutional policy for providers of this service [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/26,27,30\">",
"     26,27,30",
"    </a>",
"    ]. In one study, approximately 80 percent of patients trained on self-testing demonstrated competency. Factors associated with the inability to be competent to perform self-testing included increased age, history of prior stroke, poor cognition, and poor manual dexterity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two studies, self-management, when compared with routine clinic-based care, did not appear to be cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/26,32\">",
"     26,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain self-monitoring machines may give erroneous results in patients with hypercoagulable states (eg, presence of antiphospholipid antibodies, lupus anticoagulants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. This issue is best approached by assuring that the machine readings for the patient in question agree with those obtained at the medical center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF STRICT INR CONTROL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effects of over- and under-anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of strict INR control has been most effectively shown for anticoagulation in patients with nonvalvular atrial fibrillation. Underanticoagulation (ie, INRs &lt;2.0) has been associated with an increased risk of stroke, while overanticoagulation (ie, INR &gt;3.0) has been associated with an increased risk of bleeding (",
"    <a class=\"graphic graphic_figure graphicRef65373 \" href=\"mobipreview.htm?42/18/43296\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results have been shown for patients taking oral anticoagulants to prevent thromboembolism in a number of other conditions (",
"    <a class=\"graphic graphic_figure graphicRef78252 \" href=\"mobipreview.htm?41/27/42430\">",
"     figure 3",
"    </a>",
"    ). This was shown in a meta-analysis of 19 studies, which included patients receiving oral anticoagulation for a number of indications, including nonvalvular atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both studies indicated that the \"optimal\" therapeutic INR range, which minimized the combined risks of hemorrhage and thrombosis, was 2.0 to",
"    <span class=\"nowrap\">",
"     2.9/3.0.",
"    </span>",
"    Whether this range holds for all indications (eg, atrial fibrillation, myocardial infarction, mechanical heart valves), all end-points (eg, degrees of severity of the complication), and specific patient characteristics, is the subject of ongoing investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H11#H11\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'INR monitoring and goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An example of high quality control (ie, 84 percent of the time spent in the therapeutic range) was presented by the Leiden Thrombophilia Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/42\">",
"     42",
"    </a>",
"    ]. This was an observational report of 266 patients who received anticoagulation for a first episode of VTE for a mean duration of 6.5 months at a target INR of 2.5 to 3.5. The mean INR during this period was 2.9, with 9.7 percent of the time spent at an INR &lt;2.0 and 6.5 percent spent at an INR &gt;3.5. This contrasts with a nursing home study from Connecticut in which patients were in the therapeutic range only 50 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have suggested that improved anticoagulation control could significantly decrease the likelihood of anticoagulation-associated adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. A meta-analysis of 45 studies that assigned hemorrhagic and thromboembolic events in patients taking anticoagulants to discrete INR ranges suggested that improved anticoagulation control could decrease the likelihood of approximately one-half of all anticoagulation-associated adverse events. Findings in the 71,000 patients evaluated in this study included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Forty-four percent (95% CI 39-49 percent) of hemorrhagic events occurred at INRs above the therapeutic range",
"     </li>",
"     <li>",
"      Forty-eight percent (95% CI 41-55 percent) of thromboembolic events occurred at INRs below the therapeutic range",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A significant but lower rate of complication due to suboptimal anticoagulation was found in a retrospective cohort study from eastern Ontario evaluated anticoagulant-associated hemorrhagic and thromboembolic events in subjects &ge;65 years of age, using population-based administrative databases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/45\">",
"     45",
"    </a>",
"    ]. A total of 10,020 subjects were exposed to oral anticoagulants; they spent 14 and 27 percent of the time with excessively high or low anticoagulation intensity, respectively. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessively high anticoagulation intensity (ie, INR &gt;3.0) explained 26 percent (95% CI 19-32 percent) of all serious hemorrhagic events",
"     </li>",
"     <li>",
"      Excessively low anticoagulation intensity (ie, INR &lt;2.0) explained 11 percent (95% CI 4-18 percent) of all thromboembolic events",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Factors affecting INR control",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of variables are associated with the degree of INR control in an individual patient, producing either increased sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or increased warfarin dose requirements. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/46,48-53\">",
"     46,48-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Management setting (eg, transition from outpatient to inpatient setting and vice-versa, anticoagulation clinic, community physicians, self-management).",
"     </li>",
"     <li>",
"      Absence of a significant chronic disease burden (eg, comorbid heart failure, liver disease, alcohol abuse, cancer, diabetes).",
"     </li>",
"     <li>",
"      Patient adherence (eg, frequency of missed pill bottle openings).",
"     </li>",
"     <li>",
"      Addition or deletion of other (or multiple) medications that might influence",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      metabolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H16#H16\">",
"       \"Therapeutic use of warfarin\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alterations in dietary intake of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Influence of diet'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cutoff INR levels prompting dosage change. An observational study has suggested that better overall control can be achieved by changing the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      dose only when the INR is either &le;1.7 or &ge;3.3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Influence of diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profound week-to-week differences in the dietary content of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    are known to alter the stability of anticoagulation control with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/54-60\">",
"     54-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In different studies, the threshold for lowering the INR was 150",
"      <span class=\"nowrap\">",
"       microg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      in vitamin K replete patients and 25",
"      <span class=\"nowrap\">",
"       microg/day",
"      </span>",
"      in vitamin K depleted patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized crossover study, brief periods of changes of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      intake also had significant effects on coagulation parameters. Patients allocated to an 80 percent decrease of vitamin K intake increased their INR by 27 percent one week after the intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/54\">",
"       54",
"      </a>",
"      ]. In a similar study, for each increase of 100",
"      <span class=\"nowrap\">",
"       microg/day",
"      </span>",
"      in the daily dietary intake of vitamin K averaged over four days, the INR was reduced by 0.2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective dietary assessment study in 43 anticoagulated patients revealed that the variability in INR and changes in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      intake were inversely correlated and that a weekly change of 714 micrograms of dietary vitamin K significantly altered weekly INR by 1 unit, equal in magnitude to a weekly dose change of 14.5 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The current daily value (recommended dietary allowance) for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    is in the range of 65 to 80",
"    <span class=\"nowrap\">",
"     microg/day.",
"    </span>",
"    This amount is easily exceeded by the ingestion of one serving of green leafy vegetables (eg, one-half cup of frozen spinach contains &gt;500 micrograms of vitamin K) (",
"    <a class=\"graphic graphic_table graphicRef78708 \" href=\"mobipreview.htm?37/43/38589\">",
"     table 1",
"    </a>",
"    ). Other sources of vitamin K (eg, multivitamins, dietary supplements, herbal products) may also affect the degree of INR control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of vitamin K\", section on 'Daily value'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of increased dietary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    intake can be overcome by a higher",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/63\">",
"     63",
"    </a>",
"    ]. This is potentially important, since there is evidence that a low intake of vitamin K may be associated with a higher risk of unstable warfarin control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/64\">",
"     64",
"    </a>",
"    ], and that a high vitamin K intake reduces the risk of a low INR by lessening the influence of incidental consumption of vitamin K-rich food on the INR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/65\">",
"     65",
"    </a>",
"    ]. This was suggested in a study that evaluated 26 patients with unstable and 26 with stable control of anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/66\">",
"     66",
"    </a>",
"    ]. The patients with unstable warfarin control had a significantly lower intake of dietary vitamin K (29 versus 76",
"    <span class=\"nowrap\">",
"     microg/day).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vitamin K supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for the use of dietary supplementation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    for subjects with unstable anticoagulation control comes from a study of eight motivated patients receiving anticoagulant therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , whose INRs had been fluctuating for reasons not associated with identifiable changes in diet, warfarin dosage, activity level, illness, or changes in drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/67\">",
"     67",
"    </a>",
"    ]. Supplementation with 100",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    of vitamin K significantly increased the number of INRs in range, increased time in range, and decreased INR fluctuation.",
"   </p>",
"   <p>",
"    These observations provided the rationale for a randomized, double-blind, controlled trial of supplementation with 150",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    or placebo in 76 patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for at least nine months who were considered to have",
"    <strong>",
"     unexplained",
"    </strong>",
"    unstable INR control as defined by two criteria: the standard deviation of their INR values was &gt;0.5 and they had required at least three warfarin dose changes in the last six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/68\">",
"     68",
"    </a>",
"    ]. The following significant differences were noted in the vitamin K-treated group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As expected, a greater increase in the average daily dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was need to maintain INR control in subjects receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      (16 percent [daily dose increased from 3.8 to 4.4",
"      <span class=\"nowrap\">",
"       mg/day]",
"      </span>",
"      versus 1.5 percent). The magnitude of this effect was later shown to be related to the subject's VKORC1 genotype, being greatest in those with the GG polymorphism (+25 percent), and least (mean of zero percent) in those with the AA polymorphism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/69\">",
"       69",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H12#H12\">",
"       \"Therapeutic use of warfarin\", section on 'Vitamin K epoxide reductase complex 1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A greater reduction in INR variability, as defined by the standard deviation of INR values (-0.24 versus -0.11)",
"     </li>",
"     <li>",
"      A greater increase in the percent time spent within the target INR range (+28 versus +15 percent)",
"     </li>",
"     <li>",
"      A greater percent of patients fulfilling criteria for stable control (54 versus 21 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that patients with unexplained unstable",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    control may have improved control following the use of low-dose oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/70\">",
"     70",
"    </a>",
"    ]. Such improved control might benefit the patient in terms of decreased frequency of adverse events associated with either over- or under-anticoagulation.",
"   </p>",
"   <p>",
"    While there are no FDA-approved low-dose oral formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    , several are available from health food stores and pharmacies (for one example see reference) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35880/abstract/71\">",
"     71",
"    </a>",
"    ]. We suggest that the clinician consult",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    pharmacist to help the patient locate a vitamin K1 oral 100 mcg supplement from a highly reliable, nationally known supplier that adheres to FDA good manufacturing practices and standards.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/43/28337?source=see_link\">",
"       \"Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of a successful anticoagulation program is to ensure that the patient spends as much time as possible with an INR in the desired therapeutic range (usual target INR: 2.5, target range: 2.0 to 3.0), and that under- and over-anticoagulation are avoided (",
"      <a class=\"graphic graphic_figure graphicRef52321 \" href=\"mobipreview.htm?31/42/32429\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Two major components of a successful anticoagulation program include the outpatient setting in which this control is monitored, as well as patient-specific variables that might affect the stability of such control (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Importance of strict INR control'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest that, wherever possible, the patient be enrolled in either a self-management anticoagulation program or an anticoagulation clinic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These programs appear to offer better overall anticoagulation control and fewer anticoagulation- related side effects than standard management programs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Relative efficacy of different management programs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that, in patients with unexplained unstable",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      control, a trial of supplementation with low-dose oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      (eg, 100 to 200",
"      <span class=\"nowrap\">",
"       microg/day",
"      </span>",
"      PO) be instituted, along with close monitoring of the INR, in order to improve such control (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vitamin K supplementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/1\">",
"      van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/2\">",
"      Lane DA, Lip GY. Maintaining therapeutic anticoagulation: the importance of keeping \"within range\". Chest 2007; 131:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/3\">",
"      Fitzmaurice DA, Hobbs FD, Murray ET, et al. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med 2000; 160:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/4\">",
"      Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003; 169:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/5\">",
"      Poller L, Keown M, Ibrahim S, et al. A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage. Br J Haematol 2008; 143:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/6\">",
"      Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm 2004; 10:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/7\">",
"      Saokaew S, Permsuwan U, Chaiyakunapruk N, et al. Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. J Thromb Haemost 2010; 8:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/8\">",
"      Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest 2006; 130:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/9\">",
"      Manotti C, Moia M, Palareti G, et al. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 2001; 86:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/10\">",
"      Oake N, van Walraven C, Rodger MA, Forster AJ. Effect of an interactive voice response system on oral anticoagulant management. CMAJ 2009; 180:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/11\">",
"      Louis KM, Martineau J, Rodrigues I, et al. Primary care practices and determinants of optimal anticoagulation management in a collaborative care model. Am Heart J 2010; 159:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/12\">",
"      Metlay JP, Hennessy S, Localio AR, et al. Patient reported receipt of medication instructions for warfarin is associated with reduced risk of serious bleeding events. J Gen Intern Med 2008; 23:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/13\">",
"      Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/14\">",
"      Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Ann Pharmacother 2007; 41:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/15\">",
"      Aziz F, Corder M, Wolffe J, Comerota AJ. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg 2011; 54:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/16\">",
"      Siebenhofer A, Berghold A, Sawicki PT. Systematic review of studies of self-management of oral anticoagulation. Thromb Haemost 2004; 91:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/17\">",
"      Gardiner C, Williams K, Mackie IJ, et al. Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. Br J Haematol 2005; 128:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/18\">",
"      Fitzmaurice DA, Murray ET, McCahon D, et al. Self management of oral anticoagulation: randomised trial. BMJ 2005; 331:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/19\">",
"      Siebenhofer A, Rakovac I, Kleespies C, et al. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. Thromb Haemost 2008; 100:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/20\">",
"      Ryan F, Byrne S, O'Shea S. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost 2009; 7:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/21\">",
"      Verret L, Couturier J, Rozon A, et al. Impact of a Pharmacist-Led Warfarin Self-Management Program on Quality of Life and Anticoagulation Control: A Randomized Trial. Pharmacotherapy 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/22\">",
"      Nagler M, Raddatz-M&uuml;ller P, Schmid P, et al. Accuracy of the point-of-care coagulometer CoaguChek XS in the hands of patients. J Thromb Haemost 2013; 11:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/23\">",
"      Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010; 363:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/24\">",
"      Men&eacute;ndez-J&aacute;ndula B, Souto JC, Oliver A, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 2005; 142:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/25\">",
"      Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/26\">",
"      Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/27\">",
"      Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010; :CD003839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/28\">",
"      Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011; 154:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/29\">",
"      Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/30\">",
"      Ansell J, Jacobson A, Levy J, et al. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005; 99:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/31\">",
"      Dolor RJ, Ruybalid RL, Uyeda L, et al. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). J Thromb Thrombolysis 2010; 30:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/32\">",
"      Jowett S, Bryan S, Murray E, et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol 2006; 134:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/33\">",
"      Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/34\">",
"      Attermann J, Andersen NT, Korsgaard H, et al. Patient-specific errors in agreement between International Normalized Ratios measured by a whole blood coagulometer and by a routine plasma-based method. Haematologica 2004; 89:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/35\">",
"      Jonsson M, Hillarp A, Svensson P. Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy. Thromb Res 2004; 114:83.",
"     </a>",
"    </li>",
"    <li>",
"     Information on test limitations for the CoaguChek XS PT Test system is available on the Roche Diagnostics website www.poc.roche.com (Accessed on March 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/37\">",
"      Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/38\">",
"      Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/39\">",
"      White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/40\">",
"      Oake N, Jennings A, Forster AJ, et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008; 179:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/41\">",
"      Torn M, Cannegieter SC, Bollen WL, et al. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med 2009; 169:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/42\">",
"      Gadisseur AP, Christiansen SC, VAN DER Meer FJ, Rosendaal FR. The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study. J Thromb Haemost 2007; 5:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/43\">",
"      Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007; 120:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/44\">",
"      Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007; 176:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/45\">",
"      van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest 2007; 131:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/46\">",
"      Witt DM, Delate T, Clark NP, et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010; 8:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/47\">",
"      Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/48\">",
"      van Walraven C, Forster AJ. Anticoagulation control in the peri-hospitalization period. J Gen Intern Med 2007; 22:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/49\">",
"      Witt DM, Delate T, Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/50\">",
"      Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007; 167:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/51\">",
"      Platt AB, Localio AR, Brensinger CM, et al. Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest 2010; 137:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/52\">",
"      Rose AJ, Ozonoff A, Berlowitz DR, et al. Warfarin dose management affects INR control. J Thromb Haemost 2009; 7:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/53\">",
"      Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/54\">",
"      Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004; 116:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/55\">",
"      Schurgers LJ, Shearer MJ, Hamuly&aacute;k K, et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004; 104:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/56\">",
"      Kurnik D, Loebstein R, Rabinovitz H, et al. Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. A prospective, controlled trial. Thromb Haemost 2004; 92:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/57\">",
"      Couris R, Tataronis G, McCloskey W, et al. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. Int J Vitam Nutr Res 2006; 76:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/58\">",
"      Khan T, Wynne H, Wood P, et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004; 124:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/59\">",
"      Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care 2007; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/60\">",
"      de Assis MC, Rabelo ER, Avila CW, et al. Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial. Circulation 2009; 120:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/61\">",
"      Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006; 5:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/62\">",
"      Johnson MA. Influence of vitamin K on anticoagulant therapy depends on vitamin K status and the source and chemical forms of vitamin K. Nutr Rev 2005; 63:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/63\">",
"      Lubetsky A, Dekel-Stern E, Chetrit A, et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/64\">",
"      Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/65\">",
"      Rombouts EK, Rosendaal FR, van der Meer FJ. Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol 2010; 149:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/66\">",
"      Sconce E, Khan T, Mason J, et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/67\">",
"      Reese AM, Farnett LE, Lyons RM, et al. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 2005; 25:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/68\">",
"      Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/69\">",
"      Sconce EA, Avery PJ, Wynne HA, Kamali F. Vitamin K epoxide reductase complex subunit 1 (VKORC1 ) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. J Thromb Haemost 2008; 6:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35880/abstract/70\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.gnc.com/product/index.jsp?productId=2133377 (Accessed on May 24, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1337 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35880=[""].join("\n");
var outline_f35_2_35880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELATIVE EFFICACY OF DIFFERENT MANAGEMENT PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTICOAGULATION CLINICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22917624\">",
"      Cost effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SELF-MONITORING AND SELF-MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMPORTANCE OF STRICT INR CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effects of over- and under-anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Factors affecting INR control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Influence of diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vitamin K supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1337\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1337|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/42/32429\" title=\"figure 1\">",
"      Self measurement of INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/18/43296\" title=\"figure 2\">",
"      Events in AF according to INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/27/42430\" title=\"figure 3\">",
"      Optimal INR oral anticoag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1337|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/43/38589\" title=\"table 1\">",
"      Vitamin K foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=related_link\">",
"      Anticoagulation in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/43/28337?source=related_link\">",
"      Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_2_35881="Loin pain-hematuria syndrome";
var content_f35_2_35881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Loin pain-hematuria syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     Lee A Hebert, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     Dan N Spetie, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     Costantino Benedetti, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     Tibor Nadasdy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35881/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/2/35881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loin pain-hematuria syndrome (LPHS) was first described in 1967 in a report of three young women (20 to 28 years of age) who had recurrent episodes of severe unilateral or bilateral loin (flank) pain that were accompanied by gross or microscopic hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/1\">",
"     1",
"    </a>",
"    ]. The major causes of flank pain and hematuria were not present. Renal arteriography suggested focally impaired cortical perfusion, while renal biopsy showed interstitial fibrosis and arterial sclerosis. Since this original report, several hundred cases have been reported in the medical literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of LPHS is not well understood. Approximately one-half of our more than 200 LPHS patients reside in Central Ohio, which has a population of 1.6 million. If our patients represent one-half of those with LPHS in this region, the prevalence of LPHS is about 0.012 percent. This qualifies LPHS as a rare disease (prevalence less than 0.07 percent) according to the Rare Disease Act of 2002 (House Resolution 4013).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;LPHS is a poorly defined disorder characterized by recurrent or persistent loin (flank) pain and hematuria that appears to represent glomerular bleeding. Most patients present with both manifestations, but some present with loin pain or hematuria alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/3\">",
"     3",
"    </a>",
"    ]. Pain episodes are rarely associated with low-grade fever and dysuria, but urinary tract infection is not present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LPHS is considered primary when it occurs in the absence of an underlying acquired glomerular disease, and secondary when it occurs with an acquired glomerular disease (eg, IgA nephropathy). Among 43 consecutive patients we saw with LPHS, all had a negative urologic evaluation, 34 had primary disease and 9 had IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients are typically young (mean age 31 years in one review), predominantly female (70 to 80 percent in most series), and almost all white [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. As many as one-half of patients with LPHS have nephrolithiasis, as defined by either a history of passing stones or renal calcifications typical of stones on imaging studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors responsible for the female predominance are not well understood. Females tend to have thinner glomerular basement membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/5\">",
"     5",
"    </a>",
"    ], which may predispose to glomerular hematuria if all other factors are held constant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematuria in LPHS is typically characterized by dysmorphic red cells (primarily acanthocytes), which indicate a glomerular origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the absence of acanthocytes does not exclude LPHS. In such patients, intratubular crystal deposition may be primarily responsible for the hematuria. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Mechanism of hematuria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The hematuria can be microscopic but most patients have experienced at least one episode of gross hematuria (25 of 34 in our series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. Episodes of gross hematuria are almost always accompanied by worsening pain. These episodes usually last a few days, but gross hematuria and pain can persist for weeks to months.",
"   </p>",
"   <p>",
"    Between episodes of gross hematuria, the urinalysis typically shows microscopic hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. However, occasionally the hematuria clears but the pain is still present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomerular filtration rate, as estimated from the serum creatinine, remains normal and hypertension is not a feature of primary LPHS, although some patients have hypertension for other reasons. Protein excretion is typically normal or only slightly elevated. These general principles were illustrated our report of 34 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The mean serum creatinine was 0.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (80",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Hypertension was present in six (18 percent)",
"     </li>",
"     <li>",
"      Protein excretion was above the upper limit of normal of 150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in 11 (32 percent) but was above 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in only 2 (maximum 1635 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Loin pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain, which may be described as burning or throbbing, is localized at the costovertebral angles and made worse by a gentle punch. As with other causes of renal colic, the pain may radiate to the abdomen, inguinal area, or medial thigh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/3\">",
"     3",
"    </a>",
"    ]. The pain at presentation can be unilateral or less often bilateral (6 of 34 in the above series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the majority of patients eventually develop bilateral pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/3\">",
"     3",
"    </a>",
"    ]. The pain is induced or exacerbated by exercise in approximately one-half of patients and riding in a car can be uncomfortable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pain is typically severe, leading physicians to consider or prescribe narcotic therapy. Sleep may be difficult, since the supine position increases flank pressure. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Chronic pain control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some patients describe upper abdominal pain, but costovertebral angle punch tenderness is also present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, tenderness of the muscles overlying the costovertebral area is common because of chronic muscle spasm.",
"   </p>",
"   <p>",
"    The onset of LPHS pain is often associated with nausea and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. This can complicate management because the patient may be unable to control the pain with oral opioids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When renal biopsy is performed in patients with primary LPHS, the glomeruli are normal by light and immunofluorescence microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. However, numerous renal tubules that contain red cells or red cell casts are usually present, suggesting that glomerular bleeding is the source of hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. It is likely that glomerular hematuria is the result of structural abnormalities of the glomerular basement membrane that are not visible by light or immunofluorescence microscopy. Approximately 60 percent of biopsy specimens show thin or thick glomerular basement membranes on electron microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have observed three relatively distinct LPHS clinical presentations. The following order is the approximate frequency of their occurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Scenario 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A young woman presents to her primary care physician with moderate to severe unilateral or bilateral flank pain, and microscopic hematuria is noted. Pyelonephritis is diagnosed, although pyuria and bacteriuria are absent. An antibiotic is administered, but the pain persists. Successive renal imaging studies are normal or negative. An opioid is started with some relief.",
"   </p>",
"   <p>",
"    The patient is referred to a urologist who repeats the imaging studies and then performs cystoscopy and retrograde examination, all of which are normal. The pain continues. The urologist then places ureteral stents, but the stents do not relieve the pain.",
"   </p>",
"   <p>",
"    Symptomatic urinary tract infection ensues. The stents are removed. The infection resolves, but the patient is still miserable. She is then referred to a pain medicine specialist or a nephrologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Scenario 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient presents with unilateral flank pain and hematuria caused by an obstructing kidney stone. The kidney stone is eventually passed or removed, but the pain and hematuria persist. After multiple negative or normal urologic procedures, the patient is referred to a pain medicine specialist or a nephrologist. Narcotic-seeking behavior is suspected.",
"   </p>",
"   <p>",
"    A variation of scenario 2 is the patient who has had kidney stones in the past and now has nephrocalcinosis consistent with medullary sponge kidney or the medullary calcifications that can be seen in patients with hypercalciuria. Imaging studies show no evidence of obstruction to urine flow but the patient has severe pain, usually bilateral. Narcotic-seeking behavior is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Scenario 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serious athlete experiences flank pain and gross hematuria while playing or practicing his or her sport. The pain is of sufficient severity and the hematuria of sufficient alarm that the patient quits the sport. Numerous urologic procedures are performed, which are all normal or negative. Eventually, the patient is referred to a nephrologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Massive intrarenal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four cases of unexplained massive unilateral hemorrhage into renal tubules, requiring nephrectomy, have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/7\">",
"     7",
"    </a>",
"    ]. The glomeruli were normal by light microscopy. We hypothesized that these patients may have had structurally abnormal glomerular basement membranes that diffusely and massively ruptured, perhaps under conditions of acutely increased renal venous pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/7\">",
"     7",
"    </a>",
"    ]. Either the right or the left kidney was involved. As a result, the nutcracker syndrome, which only involves the left kidney, is not a complete explanation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H25#H25\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Nutcracker syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple hypotheses have been proposed for the hematuria and pain of LPHS, including vascular disease of the kidney, coagulopathy, renal vasospasm (including micro-infarction), and psychopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there is no objective evidence supporting these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mechanism of hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;When renal biopsy is performed, some patients have a known cause of hematuria such as IgA nephropathy or vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Such patients are considered to have secondary LPHS, while patients without signs of acquired underlying glomerular disease are considered to have primary LPHS.",
"   </p>",
"   <p>",
"    Renal biopsy in patients with primary LPHS shows evidence of glomerular hematuria, as manifested by red cells in the tubules. This finding is seen significantly more often in patients with LPHS than in normal kidneys from transplant donors (7.2 versus 1.6 percent of tubular cross-sections with red cells in a blinded assessment in the series of 34 patients), thereby precluding trauma from the biopsy as the cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. Renal biopsy also showed red cell casts in the tubules in some patients with LPHS but not in controls, another objective sign of glomerular hematuria. In addition, as mentioned above, approximately 60 percent of biopsy specimens show abnormally thin or thick glomerular basement membranes on electron microscopy, suggesting an important role for glomerular basement membrane abnormalities in the hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We consider glomerular hematuria to be present if the renal biopsy shows red cell casts, or if more than 3 percent of tubular cross-sections contain red cells, which is approximately 2 standard deviations above the mean value in normal kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. The urinalysis usually reveals evidence of glomerular hematuria, such as dysmorphic red cells (particularly acanthocytes)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    red cell casts, but the absence of acanthocytes does not exclude the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 graphicRef55778 \" href=\"mobipreview.htm?8/16/8455\">",
"     picture 1A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with LPHS do not have increased numbers of red cells in tubular cross-sections on renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. Possible explanations are that the patients did not have gross hematuria at the time that renal biopsy was performed, which is usually the case, and sampling error. The absence of demonstrable glomerular hematuria on renal biopsy does not exclude the diagnosis of primary LPHS since the LPHS patients with or without evidence of glomerular hematuria on renal biopsy are comparable with respect to age, sex, race, pain characteristics, serum creatinine, degree of protein excretion, association with nephrolithiasis, and glomerular basement membrane width [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, hematuria in primary LPHS may be due to a functionally abnormal glomerular basement membrane in which temporary gaps form that permit the passage of red blood cells into the urinary space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar gaps may be seen in normal subjects, but may occur with increased frequency in those with an abnormal glomerular basement membrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Possible role of intratubular crystal formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In as many as 50 percent of patients with primary LPHS (16 of 34 in one series), the glomerular hematuria coexists with documented nephrolithiasis, as manifested by a history of passed stones or by typical calcifications on imaging studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar findings have been described in patients with thin basement membrane nephropathy (TBMN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/11\">",
"     11",
"    </a>",
"    ]. Among 46 individuals with biopsy proven TBMN or first-degree relatives with persistent microscopic hematuria, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      18 (39 percent) had hypercalciuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperuricosuria, which are important risk factors for nephrolithiasis, and 25 percent of those with proven disease had a history of previous nephrolithiasis. These values were much higher than in patients with IgA nephropathy or normal controls (eg, 3 percent of IgA nephropathy patients had a history of nephrolithiasis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"       \"Risk factors for calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The TBMN patients and microhematuric first-degree relatives with hypercalciuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperuricosuria had, when compared to those with normal calcium and uric acid excretion, significantly higher rates of episodes of gross hematuria (44 versus 7 percent) and episodes of loin pain (27 versus 3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, renal tubular injury and obstruction may be promoted by the simultaneous presence of red cells and microcrystals in the tubular lumen, leading to gross hematuria and loin pain (",
"    <a class=\"graphic graphic_figure graphicRef55828 \" href=\"mobipreview.htm?39/36/40514\">",
"     figure 1",
"    </a>",
"    ). Whether intratubular crystal formation can cause LPHS in the absence of glomerular hematuria is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mechanism of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of loin (flank) pain in LPHS is incompletely understood. The following observations support the hypothesis that the pain of LPHS originates in the kidney:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain is localized at the costovertebral angles and made worse by a gentle punch, features that are typical of kidney pain.",
"     </li>",
"     <li>",
"      LPHS pain can be stopped at least temporarily by denervating the kidney. Denervation can be accomplished by stripping the renal capsule from the kidney (the capsule contains the stretch fibers that transmit pain sensation when the renal parenchyma expands), by renal autotransplantation, or by stripping of the renal nerves from the renal artery (neurectomy). However, many patients develop recurrent symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/3,4,12,13\">",
"       3,4,12,13",
"      </a>",
"      ], particularly after renal neurectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nephrectomy is curative but pain may recur on the contralateral side [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest the following sequence of events as a contributor to the pain in LPHS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. Glomerular hematuria, often in the presence of abnormal (thin or thick) glomerular basement membranes, is the initiating event, leading sequentially to tubular obstruction, backleak of glomerular filtrate, and local parenchymal edema leading to compression of adjacent tubules. Both the tubular obstruction and compression of adjacent tubules lead to glomerular hypertension, and further bleeding into the tubules, thereby creating a vicious cycle that eventually results in diffuse parenchymal edema, stretching of the renal capsule, and loin pain (",
"    <a class=\"graphic graphic_figure graphicRef55828 \" href=\"mobipreview.htm?39/36/40514\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As mentioned in the preceding section, hypercalciuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperuricosuria may contribute to tubular obstruction and, in patients with thin basement membrane nephropathy, are associated with significantly higher rates of episodes of loin pain than are seen in similar patients with normal calcium and uric acid excretion (27 versus 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the great majority of patients with glomerular bleeding or with urolithiasis (or its risk factors) do not have the severe and constant or frequently recurrent pain of LPHS. Thus, other factors are needed to explain the pathogenesis of pain that occurs in primary or secondary LPHS. As examples, patients with LPHS may have greater compliance of the renal capsule or qualitative or quantitative differences in the enervation of the renal capsule, each of which could enhance the susceptibility to renal pain (",
"    <a class=\"graphic graphic_figure graphicRef55828 \" href=\"mobipreview.htm?39/36/40514\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Possible somatoform pain disorder in LPHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A psychiatric component has been described and some have suggested a type of somatoform pain disorder and possible drug-seeking behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. One report compared 15 patients with LPHS to 10 patients with complicated renal stone disease who were matched for age, sex, and duration of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/14\">",
"     14",
"    </a>",
"    ]. The patients with LPHS were much more likely to have medically unexplained somatic symptoms, an adverse psychologic event preceding the onset of pain (8 versus 0), and a history of greater analgesic ingestion. The origin of hematuria was not established.",
"   </p>",
"   <p>",
"    Some patients have been management successfully with antidepressants, anxiolytics, and supportive counseling, although the hematuria may persist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/15\">",
"     15",
"    </a>",
"    ]. On the other hand, effective non-narcotic therapies can lead to long-term pain relief, cessation of drug use, and reversal of any psychiatric disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the evaluation of more than 200 patients referred to our center with unexplained flank pain and hematuria, we suggest the following step-wise approach. The diagnosis of LPHS requires exclusion of causes of nonglomerular bleeding, fulfillment of diagnostic criteria for LPHS, and renal biopsy if underlying acquired glomerular disease (eg, IgA nephropathy) is suspected in order to distinguish primary from secondary LPHS. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Primary versus secondary LPHS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Exclusion of nonglomerular bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since LPHS is an uncommon disorder, the first step in the diagnostic approach to LPHS is to exclude nonglomerular causes of loin pain and hematuria. The main causes include obstructing urolithiasis, polycystic kidney disease, renal cell carcinoma, recurrent renal papillary necrosis with obstruction, recurrent renal thromboembolism, recurrent renal artery dissection (usually associated with fibromuscular dysplasia), endometriosis, and left renal vein entrapment (nutcracker syndrome). Renal vein thrombosis is not included in this list because, although it can manifest flank pain and hematuria, the pain is not chronic or recurrent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link&amp;anchor=H6#H6\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Flank and abdominal pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11367?source=see_link\">",
"     \"Diagnosis and treatment of renal infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H25#H25\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Nutcracker syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematuria and flank pain can also be factitious, with blood being added to the urine after voiding (eg, from a finger stick). In such patients, factitious hematuria can be documented by the absence of hematuria in a urine specimen obtained under direct observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the exclusion criteria are met, the next step is to document whether a syndrome consistent with LPHS is present. We propose the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain is typical of LPHS, being severe, unilateral or bilateral, constant or frequently recurrent, localized at the costovertebral angles, made worse by gentle punching, and present for a prolonged period (six months or more). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If nephrolithiasis has occurred in the past, stones are not currently obstructing the urinary tract. The absence of obstruction should be confirmed by at least two kidney imaging procedures obtained during episodes of flank pain, preferably by ultrasonography to minimize the cumulative dose of radiation.",
"     </li>",
"     <li>",
"      Hematuria, defined as more than five red cells per high power field, is present in almost all urinalyses. In our experience, hematuria is absent in less than 5 percent of examinations and almost invariably recurs in subsequent specimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gross hematuria is almost always associated with worsening pain, but severe pain can occur in the absence of gross hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Blood clots are rarely present in the urine of LPHS patients with gross hematuria, and their presence is indicative of non-glomerular hematuria, such as with tubular damage induced by crystal formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471590#H1824471590\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Blood clots'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Primary versus secondary LPHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal biopsy is warranted in patients in whom underlying acquired glomerular disease (eg, IgA nephropathy) is suspected. Patients with underlying glomerular disease often have overt proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevation in serum creatinine, neither of which is present in primary LPHS.",
"   </p>",
"   <p>",
"    Thus, the main clinical clues to an underlying glomerular disease are the presence of increased protein excretion (greater than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or a urine",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio greater than 0.5",
"    <span class=\"nowrap\">",
"     g/g",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/18/16673?source=see_link\">",
"     calculator 1",
"    </a>",
"    )),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevation in serum creatinine, which is often defined as a serum creatinine greater than 1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [106",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in women, and greater than 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [124",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in men.",
"   </p>",
"   <p>",
"    However, these definitions will miss clinically significant elevations in serum creatinine that remain within the normal range. As an example, a woman with an increase in serum creatinine from 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44 to 88",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    has had a 50 percent reduction in glomerular filtration rate if muscle mass is stable and there are no factors that interfere with tubular creatinine secretion or spuriously increase the serum creatinine concentration. Such a decline in glomerular filtration rate is not seen in LPHS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another possible indication for renal biopsy is the presence of severe and chronic kidney pain that requires substantial opioid therapy. There are at least two potential benefits from this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal biopsy may detect an unanticipated and potentially treatable condition (eg, interstitial nephritis or an infiltrative process such as lymphoma).",
"     </li>",
"     <li>",
"      Renal biopsy may document glomerular hematuria, which would provide objective evidence that a renal disease is present. This may be helpful for LPHS patients who often sense that others suspect them of malingering.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of LPHS, primary or secondary, is not well defined. We believe that LPHS eventually resolves in most patients. This conclusion is based upon our experience that LPHS is unusual in persons older than 60 years of age, and that neither end-stage kidney disease nor premature death is a feature of LPHS. A possible explanation for spontaneous resolution is that the glomeruli that bleed eventually become nonfunctional due to tubular damage. If the destroyed nephrons represent only a minority of the nephrons, the LPHS will resolve and the patient is left with near normal kidney function.",
"   </p>",
"   <p>",
"    With regard to morbidity, approximately 15 percent of our primary LPHS patients eventually develop a 24-hour urine",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio greater than 0.5.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of LPHS is the same in primary and secondary LPHS, unless the latter is due to a glomerular disease for which there is specific therapy.",
"   </p>",
"   <p>",
"    There have been no randomized trials evaluating the treatment of LPHS. The following approach is largely based upon our experience in the care of over 200 patients with this disorder. The intensity of therapy varies with the severity of the pain. Patients with severe pain typically require high-dose opioids daily or almost daily, frequently visit the emergency department, and occasionally require hospitalization for intravenous opioid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with LPHS have normal renal function and renal ultrasonography excludes renal stone disease and other disorders. They should therefore be reassured that their kidneys are functioning well and should continue to do so. Patients should also be advised to avoid activities that induce LPHS pain, such as exercise in approximately one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that administration of an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) may reduce both the frequency and severity of episodes of gross hematuria and loin pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/9\">",
"     9",
"    </a>",
"    ]. In a report of seven LPHS patients who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    for 7 to 48 months, four reported fewer or less severe episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/9\">",
"     9",
"    </a>",
"    ]. A possible mechanism for such a benefit is that efferent arteriolar dilation induced by decreased angiotensin II activity reduces intraglomerular pressure and therefore the likelihood of glomerular rupture and hematuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Reduce the risk of nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, as many as one-half of patients with LPHS have nephrolithiasis, as defined by either a history of passing stones or renal calcifications typical of stones on imaging studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ]. It is possible that renal tubular injury and obstruction is promoted by the simultaneous presence of red cells and microcrystals in the tubular lumen, leading to gross hematuria and loin pain. We have observed calcium oxalate microcrystals obstructing distal nephrons in the kidney biopsy of several LPHS patients, even though there was no history of nephrolithiasis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Possible role of intratubular crystal formation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon these observations, we recommend 24-hour urine collection for calcium, uric acid, oxalate, citrate, sodium and urine urea nitrogen (to estimate urine protein intake) even in patients who have no history of stone disease. If an abnormality is found in patients with significant LPHS symptoms, a trial of corrective therapy (eg, increased fluid intake, low salt diet for hypercalciuria, potassium citrate for hypocitraturia,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or reduced meat intake for hyperuricosuria) is reasonable to see if the frequency or severity of gross hematuria and pain is reduced. There are, however, no confirmatory data supporting this approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Chronic pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical (nonopioid and opioid) and interventional therapies for pain control in LPHS are generally similar to those in patients with other chronic pain syndromes. Every effort should be made to avoid opioid therapy. If opioids are necessary, particularly for daily therapy, consultation with a pain specialist is recommended. These long-term therapies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=see_link&amp;anchor=H415115619#H415115619\">",
"     \"Prescription drug abuse and addiction: Prevention, identification, and management\", section on 'Treatment with controlled medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment of exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with LPHS pain exacerbations that do not respond to nonopioid therapy, we typically prescribe hydrocodone (5",
"    <span class=\"nowrap\">",
"     mg/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"      acetaminophen",
"     </a>",
"    </span>",
"    500 mg, one or two tablets every four hours as needed). To avoid acetaminophen toxicity, this regimen should be temporary, should not exceed six tablets per day, and the patient should avoid alcohol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preferred opioids for moderate to severe break-through pain therapy are either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    (5-10 mg every 4 hours as needed), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    (4 mg every four hours as needed). Transmucosal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (400 micrograms every 3 to 4 hours as needed) is effective for breakthrough pain and is popular with the patients; however, it is very expensive and there are concerns about increased addiction potential and abuse not only by the patient but also by friends and relatives. We avoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    because the associated euphoria reported may increase the potential for addiction.",
"   </p>",
"   <p>",
"    We no longer prescribe home intravenous opioid therapy to treat exacerbations of primary LPHS. Each time this approach was used, it led to opioid abuse and to infections of the central venous access, which may have resulted from poor aseptic technique due to the opioid use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Inpatient therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea is often a dominant symptom during exacerbations of LPHS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"     2",
"    </a>",
"    ], and may preclude the use of oral opioids. Acutely managing pain with intravenous opioids and antiemetics in the emergency department seldom provides sufficient relief of pain and nausea. As a result, hospitalization is required for pain control. The Pain Service should be consulted.",
"   </p>",
"   <p>",
"    In our experience, three to five days of intravenous opioids is usually sufficient to break the pain cycle. We also allow an additional hospital day to transition from the intravenous opioid regimen to the patient's usual outpatient opioid regimen.",
"   </p>",
"   <p>",
"    The typical intravenous regimen involves opioid administration using a patient-controlled analgesia (PCA) pump. If the 24-hour dose that is required to control the patient's pain is known, then about 50 percent of the opioid hourly dose is given as a constant infusion. For example, a patient who requires 48 mg of IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    over 24 hours can be given 1 mg per hour as a continuous infusion. If the 24-hour total dose is not known, it is safer to start the intravenous therapy with PCA boluses without a continuous infusion for at least 24 hours. Once the 24-hour dose has been determined, the continuous infusion can be started as described above. The conversion of the oral opioid to intravenous opioid is as follows: 20 mg of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    is equivalent to 1 mg of intravenous hydromorphone; 3 mg of oral morphine is equal to 1 mg of intravenous morphine, and 6 mg of oral hydromorphone is equivalent to 1 mg of intravenous hydromorphone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link&amp;anchor=H622751254#H622751254\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Patient-controlled analgesia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is usually necessary to administer an antiemetic such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    . Ondansetron is much more expensive but, unlike promethazine, it can control nausea without increasing sedation. Other important management issues include prevention of opioid-induced constipation or urinary retention, and maintenance of hydration, because the patients may not be eating properly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pruritus is a common opioid side effect, especially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    use. Management of pruritus can involve switching from morphine to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    for symptomatic relief since the pruritus with morphine may be secondary to histamine release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Invasive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of invasive therapies have been used in the treatment of severe chronic pain syndromes. These approaches are discussed in detail elsewhere but the limited experience in LPHS will be reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Implantable intrathecal pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who require particularly large doses of opioids, the systemic side effects which may become intolerable, may be candidates for an implantable drug delivery system (IDDS) that permits intrathecal administration of opioid, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/18\">",
"     18",
"    </a>",
"    ]. The advantage of this route of administration is the ability to get the opioid directly to the opioid receptors in the spinal cord, thereby reducing the systemic concentration and minimizing side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the invasive therapies we have used in patients with LPHS, the IDDS has been the most effective. Among 17 treated patients, pain was largely controlled and hospitalization and emergency department visits were substantially reduced (unpublished personal observation). Our longest treated patient has been receiving intrathecal therapy since 1995. It should be noted that some patients, treated with IDDS, may still need occasional oral opioids for breakthrough pain.",
"   </p>",
"   <p>",
"    Limitations to the IDDS include its high cost and the risk of developing intrathecal catheter-tip inflammatory masses due to mast cell granulomas that are induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. These lesions can act as space-occupying lesions and produce neurologic symptoms. In our experience, switching from morphine to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    appears to prevent progression of the granulomas. Limited data suggest that cessation of opioid therapy through the catheter is associated with shrinkage or resolution of the mass over two to five months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although rare, infection can occur with IDDS use. In slender individuals, the subcutaneous pump is conspicuous and may be cosmetically objectionable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other invasive modalities have been evaluated in patients with LPHS, but none has proven clinically useful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulse radio frequency &mdash; The application of pulse radio frequency to the lower thoracic dorsal root ganglion has been used in some chronic pain syndromes. It disables the pain fibers for periods of up to six months but does not destroy them. We have had some success with this technique in 10 patients. However, proof of long-term benefit is lacking.",
"     </li>",
"     <li>",
"      Celiac plexus block &mdash; Celiac plexus block has been used to treat chronic upper abdominal pain, primarily in patients with cancer or chronic pancreatitis. We have not found this approach to be consistently effective in patients with LPHS and formation of a retroperitoneal hematoma at the site of the injection can add to the pain burden. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"       \"Cancer pain management: Interventional therapies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retrograde",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      infusion &mdash; Retrograde infusion of capsaicin into the ureter and renal pelvis of the painful kidney has been performed with the rationale is that capsaicin blocks the sympathetic C fibers that transmit pain sensation. This approach is not effective or safe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. A systematic review demonstrated that capsaicin infusion produced only temporary pain relief (eg, weeks), was not effective with repeated use, and led to removal of the treated kidney in 20 to 67 percent of instances because of fibrosis of the ureter, renal pelvis, or the kidney itself [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Surgical renal denervation and renal autotransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal denervation can be achieved by renal neurectomy, renal capsule stripping, or renal autotransplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/3,4,12,13,24\">",
"     3,4,12,13,24",
"    </a>",
"    ]. We do not typically recommend major surgical interventions to control LPHS pain since LPHS eventually resolves; since the pain can recur even though extraordinary steps are taken to prevent re-enervation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/18\">",
"     18",
"    </a>",
"    ]; and because there is possible harm from acute and chronic complications of the procedure.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two series, each with 24 patients undergoing renal denervation, the long-term rate of being free of pain was 25 percent at a mean follow-up of 17 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/12\">",
"       12",
"      </a>",
"      ] and 33 percent at a mean follow-up of eight years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/4\">",
"       4",
"      </a>",
"      ]. Recurrent pain is presumed to reflect renervation of the kidney.",
"     </li>",
"     <li>",
"      The long-term results may be better with renal autotransplantation. In two reports of 40 and 26 patients undergoing renal autotransplantation, the long-term rate of being free of pain was 76 percent at a mean follow-up of 8.4 years (including eight of ten who underwent bilateral autotransplantation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/4\">",
"       4",
"      </a>",
"      ] and 69 percent at a mean follow-up of 7.1 years (another 12 percent had reduced analgesic requirements and improved quality of life despite recurrent pain) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/13\">",
"       13",
"      </a>",
"      ]. In addition, three of four patients who developed recurrent pain after renal denervation in the first study were treated successfully with renal autotransplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a lower rate of being pain-free has been described by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/24\">",
"     24",
"    </a>",
"    ] and renal autotransplantation may be associated with significant complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/13,24\">",
"     13,24",
"    </a>",
"    ]. In the series of 26 patients who underwent renal autotransplantation, two required nephrectomy because of complications, one due to renal vein thrombosis and one due to persistent renal ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrectomy to control LPHS pain is never recommended, although it may be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/13\">",
"     13",
"    </a>",
"    ]. There are three case reports of LPHS patients who had bilateral nephrectomy for severe chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Although the pain was controlled, the patients were hemodialysis dependent. One patient in whom the pain disappeared for the first time in 40 years underwent successful renal transplantation and was doing well at four years although he had intermittent microscopic hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Sodium thiosulfate infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    infusion is that tubular obstruction with calcium oxalate microcrystals may contribute to the pain of LPHS (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Loin pain'",
"    </a>",
"    above). In contrast to calcium oxalate, calcium thiosulfate is highly soluble [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35881/abstract/28\">",
"     28",
"    </a>",
"    ]. Because sodium thiosulfate is excreted almost exclusively in urine, these infusions should dissolve calcium deposits in the urinary tract.",
"   </p>",
"   <p>",
"    Despite this theoretical rationale, long-term (3 to 17 months) daily therapy with 25 g of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    in 500 mL of isotonic saline failed to consistently improve pain or reduce renal calcifications in the 12 LPHS patients in whom this therapy was tried (unpublished personal observations).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the assumption that the pain of primary LPHS might be related to ischemia (\"angina\" of the kidney), we have tried therapies to increase renal blood flow with saline infusion, dopamine infusion, and oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    . None of these interventions has been successful in acutely relieving pain. Acupuncture has also been ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/59/23474?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/35/37426?source=see_link\">",
"       \"Patient information: Glomerular disease overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603935\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loin pain-hematuria syndrome (LPHS) is a rare disease with an estimated prevalence in the population of about 0.012 percent. LPHS is considered primary when it occurs in the absence of an underlying acquired glomerular disease, and secondary when it occurs with an acquired glomerular disease (eg, IgA nephropathy). LPHS is considered to be primary if the hematuria is the result of a constitutive condition (eg, abnormally thin or thick GBM). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several common clinical presentations of LPHS, but they all include the following clinical features characteristic of LPHS: (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Recurrent or persistent loin (flank) pain &minus; The pain, which may be described as burning or throbbing, is localized at the costovertebral angles, and is associated with costovertebral angle tenderness. The pain can be unilateral or, less often, bilateral, and is often induced or exacerbated by exercise and riding in a car. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Loin pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematuria &minus; The hematuria is usually microscopic and is characterized by dysmorphic red cells indicating a glomerular origin. Most patients experience at least one episode of gross hematuria, which is almost always accompanied by worsening pain. Between episodes of gross hematuria, the urinalysis ordinarily shows microscopic hematuria. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hematuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The glomerular filtration rate, remains normal or near normal in patients with LPHS, and the incidence of hypertension is not increased compared with the general population. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Renal function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal biopsy in patients with primary LPHS reveals normal glomeruli by light and immunofluorescence microscopy; red cells or red cell casts are present in the tubules, suggesting that glomerular bleeding is the source of hematuria. By electron microscopy, thin or thick glomerular basement membranes are noted in approximately 60 percent of specimens. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renal biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms for hematuria and pain in patients with LPHS are not known. The hematuria in primary LPHS may be due to functionally abnormal glomerular basement membranes, in which temporary gaps form that permit the passage of red blood cells into the urinary space. Glomerular hematuria may be the initiating event in the development of loin pain by causing tubular obstruction leading to backleak of glomerular filtrate, parenchymal edema, and stretching of the renal capsule (",
"      <a class=\"graphic graphic_figure graphicRef55828 \" href=\"mobipreview.htm?39/36/40514\">",
"       figure 1",
"      </a>",
"      ). The common occurrence of nephrolithiasis or risk factors for nephrolithiasis in patients with LPHS suggests that intratubular crystals may play a role in the bleeding and pain. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pathogenesis'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      To make a diagnosis of LPHS, the following criteria should be met: (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hematuria, defined as more than five red cells per high power field, should be present in almost all urinalyses. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent or persistent pain (present for six months or more), should be severe, localized in the costovertebral angles, and be associated with costovertebral angle tenderness. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonglomerular bleeding, for example nephrolithiasis, urinary infection, polycystic kidney disease, and tumors, must be excluded. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Exclusion of nonglomerular bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstruction of the urinary tract should not be present, and should be confirmed by at least two imaging procedures during episodes of pain. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal biopsy is warranted in patients in whom underlying acquired glomerular disease (eg, IgA nephropathy) is suspected. Patients with underlying acquired glomerular disease often have overt proteinuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an elevation in serum creatinine, neither of which is likely in primary LPHS. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Primary versus secondary LPHS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LPHS is unusual in persons older than 60 years of age, and is",
"      <strong>",
"       not",
"      </strong>",
"      associated with end-stage kidney disease or premature death. Thus, we believe that LPHS eventually resolves in most patients. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of substantial data, our treatment recommendations are experiential:",
"     </li>",
"     <li>",
"      Angiotensin inhibition with angiotensin converting enzyme inhibitors or angiotensin receptor blockers may reduce the frequency and severity of hematuria and pain episodes. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Angiotensin inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the associations with nephrolithiasis, patients with LPHS should undergo a metabolic stone workup to evaluate risk factors for kidney stones. Abnormalities that are uncovered should be treated appropriately; if none are revealed, then empiric therapy should be attempted to see if the frequency of symptoms can be reduced. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Reduce the risk of nephrolithiasis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=see_link\">",
"       \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic and acute pain control, similar to that provided to patients with other chronic pain syndromes, should be provided. Non-opioid therapy should be attempted first. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Chronic pain control'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Treatment of exacerbations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of invasive and experimental therapies have been used in the treatment of severe pain in patients with LPHS. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Invasive therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Surgical renal denervation and renal autotransplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Sodium thiosulfate infusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/1\">",
"      Little PJ, Sloper JS, de Wardener HE. A syndrome of loin pain and haematuria associated with disease of peripheral renal arteries. Q J Med 1967; 36:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/2\">",
"      Spetie DN, Nadasdy T, Nadasdy G, et al. Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis 2006; 47:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/3\">",
"      Dube GK, Hamilton SE, Ratner LE, et al. Loin pain hematuria syndrome. Kidney Int 2006; 70:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/4\">",
"      Sheil AG, Chui AK, Verran DJ, et al. Evaluation of the loin pain/hematuria syndrome treated by renal autotransplantation or radical renal neurectomy. Am J Kidney Dis 1998; 32:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/5\">",
"      Monnens LA. Thin glomerular basement membrane disease. Kidney Int 2001; 60:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/6\">",
"      Tryggvason K, Patrakka J. Thin basement membrane nephropathy. J Am Soc Nephrol 2006; 17:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/7\">",
"      Iliff WJ, Galdabini JJ. Massive intratubular hemorrhage with herniations into renal veins requiring nephrectomy. J Urol 1972; 108:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/8\">",
"      G&oacute;rriz JL, Sancho A, Ferrer R, et al. Renal-limited polyarteritis nodosa presenting with loin pain and haematuria. Nephrol Dial Transplant 1997; 12:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/9\">",
"      Hebert LA, Betts JA, Sedmak DD, et al. Loin pain-hematuria syndrome associated with thin glomerular basement membrane disease and hemorrhage into renal tubules. Kidney Int 1996; 49:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/10\">",
"      Collar JE, Ladva S, Cairns TD, Cattell V. Red cell traverse through thin glomerular basement membranes. Kidney Int 2001; 59:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/11\">",
"      Praga M, Mart&iacute;nez MA, Andr&eacute;s A, et al. Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis. Kidney Int 1998; 54:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/12\">",
"      Greenwell TJ, Peters JL, Neild GH, Shah PJ. The outcome of renal denervation for managing loin pain haematuria syndrome. BJU Int 2004; 93:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/13\">",
"      Chin JL, Kloth D, Pautler SE, Mulligan M. Renal autotransplantation for the loin pain-hematuria syndrome: long-term followup of 26 cases. J Urol 1998; 160:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/14\">",
"      Lucas PA, Leaker BR, Murphy M, Neild GH. Loin pain and haematuria syndrome: a somatoform disorder. QJM 1995; 88:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/15\">",
"      Lall R, Mailis A, Rapoport A. Hematuria-loin pain syndrome: its existence as a discrete clinicopathological entity cannot be supported. Clin J Pain 1997; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/16\">",
"      Bultitude M, Young J, Bultitude M, Allan J. Loin pain haematuria syndrome: distress resolved by pain relief. Pain 1998; 76:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/17\">",
"      Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985; 62:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/18\">",
"      Prager JP, DeSalles A, Wilkinson A, et al. Loin pain hematuria syndrome: pain relief with intrathecal morphine. Am J Kidney Dis 1995; 25:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/19\">",
"      Hassenbusch S, Burchiel K, Coffey RJ, et al. Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med 2002; 3:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/20\">",
"      Yaksh TL, Hassenbusch S, Burchiel K, et al. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med 2002; 3:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/21\">",
"      McMillan MR, Doud T, Nugent W. Catheter-associated masses in patients receiving intrathecal analgesic therapy. Anesth Analg 2003; 96:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/22\">",
"      Playford D, Kulkarni H, Thomas M, et al. Intra-ureteric capsaicin in loin pain haematuria syndrome: efficacy and complications. BJU Int 2002; 90:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/23\">",
"      Uzoh CC, Kumar V, Timoney AG. The use of capsaicin in loin pain-haematuria syndrome BJUI 2008; 103:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/24\">",
"      Parnham AP, Low A, Finch P, et al. Recurrent graft pain following renal autotransplantation for loin pain haematuria syndrome. Br J Urol 1996; 78:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/25\">",
"      Talic RF, Parr N, Hargreave TB. Anephric state after graft nephrectomy in a patient treated with renal autotransplantation for bilateral metachronous loin pain/hematuria syndrome. J Urol 1994; 152:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/26\">",
"      Winearls CG, Bass C. The loin pain haematuria syndrome. Nephrol Dial Transplant 1994; 9:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/27\">",
"      Diwakar R, Andrews PA. Renal transplantation in a patient with loin pain hematuria syndrome. Clin Nephrol 2006; 66:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35881/abstract/28\">",
"      Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985; 23:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7203 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35881=[""].join("\n");
var outline_f35_2_35881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H603935\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Loin pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical presentations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Scenario 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Scenario 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Scenario 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Massive intrarenal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mechanism of hematuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Possible role of intratubular crystal formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mechanism of pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Possible somatoform pain disorder in LPHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Exclusion of nonglomerular bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Primary versus secondary LPHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Reduce the risk of nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Chronic pain control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment of exacerbations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Inpatient therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Invasive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Implantable intrathecal pump",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Surgical renal denervation and renal autotransplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Sodium thiosulfate infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603935\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7203|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/36/40514\" title=\"figure 1\">",
"      Pain Pathogenesis LPHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7203|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/0/24591\" title=\"picture 1A\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/47/14079\" title=\"picture 1B\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/38/35424\" title=\"picture 1C\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/18/16673?source=related_link\" title=\"calculator 1\">",
"      Calculator: Urinary protein excretion estimation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11367?source=related_link\">",
"      Diagnosis and treatment of renal infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=related_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/35/37426?source=related_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=related_link\">",
"      Prescription drug abuse and addiction: Prevention, identification, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_2_35882="Management of acute severe traumatic brain injury";
var content_f35_2_35882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of acute severe traumatic brain injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35882/contributors\">",
"     J Claude Hemphill, III, MD, MAS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35882/contributors\">",
"     Nicholas Phan, MD, FRCSC, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35882/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35882/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/2/35882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/2/35882/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/2/35882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25687318\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic brain injury (TBI) is the leading cause of death in North America for individuals between the ages of 1 to 45 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/1\">",
"     1",
"    </a>",
"    ]. Many survivors live with significant disabilities, resulting in major socioeconomic burden as well. In 2000, the economic impact of TBI in the United States was estimated to be $9.2 billion in lifetime medical costs and $51.2 billion in productivity losses.",
"   </p>",
"   <p>",
"    One of the major advances over the past two decades in the care of patients with severe head injury has been the development of standardized approaches that follow international and national guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The intent of these guidelines has been to use existing evidence to provide recommendations for current care in order to lessen heterogeneity and improve patient outcomes. Unfortunately, the lack of randomized clinical trials addressing many aspects of care of the severe TBI patient has meant that the strength of supporting data for most treatment concepts is relatively weak. Despite this caveat, there is evidence that treatment in centers with neurosurgical support, especially in settings where protocol-driven neurointensive care units operate based on the above-referenced guidelines, is associated with better patient outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. Many expert panels recommend that treatment of severe TBI should be centralized in large trauma centers that offer neurosurgical treatment and access to specialized neurocritical care.",
"   </p>",
"   <p>",
"    Patients with severe head injury may frequently have other traumatic injuries to internal organs, lungs, limbs, or the spinal cord. Thus, the management of the patient with severe head injury is often complex and requires a multi-disciplinary approach and lends itself to protocol-based treatment and standardized hospital order sets derived from the previously referenced guidelines.",
"   </p>",
"   <p>",
"    This topic discusses the management of acute severe traumatic brain injury. The epidemiology and pathophysiology of traumatic brain injury, the management of mild traumatic brain injury, acute spinal cord injury, and other aspects of care of the trauma patient are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39062?source=see_link\">",
"     \"Traumatic brain injury: Epidemiology, classification, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3481?source=see_link\">",
"     \"Skull fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prehospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of prehospital management for severe head injury is to prevent hypotension and hypoxia, two systemic insults known to be major causes of secondary injury after TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. In a meta-analysis of clinical trials and population-based studies, hypoxia (PaO2 &lt;60 mmHg) and hypotension (systolic BP &lt;90 mmHg) were present in 50 and 30 percent of patients, respectively, and were each associated with a higher likelihood of a poor outcome: hypoxia (OR 2.14); hypotension (OR 2.67) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/13\">",
"     13",
"    </a>",
"    ]. Changes in prehospital management that aim to normalize oxygenation and blood pressure have improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early endotracheal intubation is generally recommended for patients with a Glasgow coma scale score of 8 or less if performed by well-trained personnel (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      ). The value of prehospital intubation is controversial, with studies finding conflicting results. In one randomized trial of 312 patients with severe TBI performed in Australia, prehospital rapid sequence intubation by paramedics was associated with better functional outcome at six months compared with intubation in hospital (51 versus 39 percent of patients with favorable outcome on Glasgow outcome scale) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/23\">",
"       23",
"      </a>",
"      ]. However, another study in San Diego, CA found that prehospital intubation was associated with an increased mortality, perhaps due to inadvertent hyperventilation, transient hypoxia, or longer time at scene prior to transport [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/24\">",
"       24",
"      </a>",
"      ]. A benefit from prehospital intubation by paramedics requires extensive training and is not widely generalizable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/25\">",
"       25",
"      </a>",
"      ]. If this expertise is not available, bag-mask ventilation is recommended.",
"     </li>",
"     <li>",
"      Prevention of hypotension in the prehospital setting is best accomplished by adequate fluid resuscitation using isotonic crystalloids. Studies of hypertonic saline in the prehospital setting have not suggested benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Saline is preferred over albumin; the latter was associated with increased mortality in one randomized study of patients with TBI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with TBI should be assumed to have a spinal fracture and appropriate precautions taken to stabilize and immobilize the spine during transport. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prehospital assessment of the Glasgow coma scale can be helpful for early triage decisions (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The prehospital management of the trauma patient is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Emergency department",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early hospital admission phase of patients with severe head injury, treatment and diagnostic assessment is done according to the ATLS (Advanced Trauma Life Support) protocol:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adequate oxygenation (PaO2 &gt;60 mmHg) and blood pressure support (systolic BP &gt;90 mmHg) continue to be priorities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11784?source=see_link\">",
"       \"Emergency airway management in the patient with elevated ICP\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vital signs including heart rate, blood pressure, respiratory status (pulse oximetry, capnography), and temperature require ongoing monitoring.",
"     </li>",
"     <li>",
"      A neurologic examination should be completed as soon as possible to determine the clinical severity of the TBI. The Glasgow coma scale (GCS) is commonly used to assess and communicate neurologic status in this setting (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      ). A GCS score of 8 or lower is considered a severe TBI. Neurologic status should be continuously assessed. Deterioration is common in the initial hours after the injury.",
"     </li>",
"     <li>",
"      The patient should be assessed for other systemic trauma.",
"     </li>",
"     <li>",
"      A complete blood count, electrolytes, glucose, coagulation parameters, blood alcohol level, and urine toxicology should be checked. Coagulopathy is common in patients with severe TBI, either resulting from patient medications or as a consequence of the trauma itself. When the INR is elevated, then efforts to reverse the coagulopathy should begin immediately. (See",
"      <a class=\"local\" href=\"#H7527255\">",
"       'Hemostatic therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23242?source=see_link\">",
"       \"Coagulopathy associated with trauma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Efforts to evaluate and manage increased intracranial pressure (ICP) should begin in the emergency department. Patients with severe TBI (GCS &le;8) and clinical symptoms suggesting possible impending herniation from elevated ICP (unilaterally or bilaterally fixed and dilated pupil(s), decorticate or decerebrate posturing, bradycardia, hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory depression) should be treated urgently, with head elevation, hyperventilation, and osmotic therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    iv) concurrently with neuroimaging and other assessments. The evaluation and management of increased ICP are discussed in detail below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Intracranial pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with TBI should be transferred to a hospital with neurosurgical services as soon as they are hemodynamically stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is the preferred imaging modality in the acute phase of head trauma and should be performed as quickly as possible. CT scan will detect skull fractures, intracranial hematomas, and cerebral edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68102 graphicRef67573 graphicRef53951 graphicRef56200 \" href=\"mobipreview.htm?34/51/35642\">",
"     image 1A-D",
"    </a>",
"    ). Current guidelines recommend head CT in all TBI patients with a Glasgow coma scale of 14 or lower (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Follow-up CT scanning should be performed if there is any clinical deterioration. Evolution of CT findings is common and may indicate an alternative treatment approach in a significant number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. While there is no clear indication for routine follow-up CT scans in the absence of clinical change or changes in physiological parameters such as ICP, practice varies considerably in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Many centers do routinely order follow-up imaging. Of note, parenchymal contrast extravasation, as with spontaneous intracerebral hemorrhage, may predict a higher risk of hemorrhage progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H6#H6\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Hemorrhage enlargement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for emergency surgery after severe head injury are based upon neurologic status, usually defined by the Glasgow coma scale (GCS) (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ), and findings on head CT criteria such as large hematoma volume or thickness and evidence of mass effect including midline shift (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68102 \" href=\"mobipreview.htm?22/0/22530\">",
"     image 1A",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epidural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical guidelines recommend evacuation of an epidural hematoma (EDH) larger than 30 mL in volume regardless of a patient's GCS score; urgent surgical evacuation is recommended for patients with acute EDH and coma (GCS score &le;8) who have pupillary abnormalities (anisocoria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19112?source=see_link&amp;anchor=H12#H12\">",
"     \"Intracranial epidural hematoma in adults\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Subdural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute subdural hematomas (SDH) &gt;10 mm in thickness or associated with midline shift &gt;5 mm on CT should be surgically evacuated, regardless of the patient's GCS score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, surgery is recommended if the GCS score is &le;8 or if the GCS score has decreased by &ge;2 points from the time of injury to hospital admission,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the patient presents with asymmetric or fixed and dilated pupils,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intracranial pressure measurements are consistently &gt;20 mmHg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43767?source=see_link&amp;anchor=H9#H9\">",
"     \"Subdural hematoma in adults: Prognosis and management\", section on 'Acute SDH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intracerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical evacuation of a traumatic intracerebral hemorrhage (ICH) in the posterior fossa is recommended when there is evidence of significant mass effect (distortion, dislocation, obliteration of the fourth ventricle, compression of the basal cisterns, or obstructive hydrocephalus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For traumatic ICH involving the cerebral hemispheres, surgical indications are not as clearly defined. Consensus surgical guidelines recommend craniotomy with evacuation if the hemorrhage exceeds 50 cm",
"    <sup>",
"     3",
"    </sup>",
"    in volume, or if the GCS score is 6 to 8 in a patient with a frontal or temporal hemorrhage greater than 20 cm",
"    <sup>",
"     3",
"    </sup>",
"    with midline shift of at least 5 mm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cisternal compression on CT scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Penetrating injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial debridement and dural closure to prevent CSF leak is generally recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/41\">",
"     41",
"    </a>",
"    ]. Small entry wounds can be treated with simple closure. Aggressive debridement and removal of deep foreign bodies such as bone or bullet fragments have not been shown to be effective in preventing delayed infection. The use of prophylactic broad-spectrum antibiotics (usually a cephalosporin) is routine in this setting and is believed to have contributed to the reduced incidence of infection in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Depressed skull fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevation and debridement are recommended for open skull fractures depressed greater than the thickness of the cranium or if there is dural penetration, significant intracranial hematoma, frontal sinus involvement, cosmetic deformity, wound infection or contamination, or pneumocephalus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3481?source=see_link\">",
"     \"Skull fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13704?source=see_link\">",
"     \"Skull fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Decompressive craniectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a decompressive craniectomy, a substantial portion of the skull is removed in order to reduce increased intracranial pressure (ICP). This can be done in combination with an evacuation procedure or as a primary treatment for increased ICP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/44\">",
"     44",
"    </a>",
"    ]. Use of this technique is controversial and its efficacy in TBI is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. Clinical trials are in progress, with a pilot study in children suggesting favorable results on both ICP and clinical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial in 155 adults with severe diffuse TBI with elevated ICP refractory to other therapies compared bifrontal decompressive craniectomy with continued standard care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/52\">",
"     52",
"    </a>",
"    ]. Surgery was associated with decreased ICP and shorter stays in the intensive care unit, but worse outcome on the extended Glasgow outcome scale at six months. The study has been criticized for having a baseline imbalance in TBI severity between the treatment groups, a relatively low threshold for elevated ICP, and a short time window for defining it to be treatment resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/53\">",
"     53",
"    </a>",
"    ]. Also, the surgical procedure used in this study is not representative of that most often performed in clinical care. Other clinical trials are in progress.",
"   </p>",
"   <p>",
"    This procedure, its complications, and its efficacy in settings other than TBI are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H38#H38\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Decompressive craniectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/569?source=see_link\">",
"     \"Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INTENSIVE CARE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal focus of critical care management for severe TBI is to limit secondary brain injury. In general, treatment efforts are aimed at intracranial pressure management and maintenance of cerebral perfusion as well as optimizing oxygenation and blood pressure and managing temperature, glucose, seizures, and other potential secondary brain insults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General medical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of BP (systolic &gt;90 mmHg) and oxygenation (PaO2 &gt;60 mmHg) remain priorities in the management of TBI patients in the ICU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/12\">",
"     12",
"    </a>",
"    ]. These should be continuously monitored. Isotonic fluids (normal saline) should be used to maintain euvolemia. A subgroup analysis in the large SAFE study found that for patients with TBI, fluid resuscitation with albumin was associated with a higher mortality as compared with normal saline (33 versus 20 percent); this risk was even more pronounced in those with severe TBI (42 versus 22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/28\">",
"     28",
"    </a>",
"    ]. Electrolyte imbalances are common in patients with TBI and should be regularly assessed along with other laboratory parameters.",
"   </p>",
"   <p>",
"    Other extracranial traumatic injuries are managed simultaneously. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    The prevention of deep venous thrombosis (DVT) is a difficult management issue in TBI. Patients with TBI are at increased risk of DVT which can be reduced by the use of mechanical thromboprophylaxis using intermittent pneumatic compression stockings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. While DVT risk can be further reduced with antithrombotic therapy, this has to be weighed against the potential risk of hemorrhage expansion, which is greatest in the first 24 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. The use and timing of antithrombotic agents in patients with TBI must therefore be individualized according to the degree of intracranial bleeding and the perceived risk of DVT. Observational studies suggest that antithrombotic therapy may not be associated with the increased risk of intracranial hemorrhage expansion previously thought to occur in this setting, even when administered early on, however, this has not been confirmed in a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=see_link&amp;anchor=H5#H5\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\", section on 'Prevention of VTE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nutritional support should not be neglected in patients with TBI. Undernutrition is associated with higher mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Patients should be fed to full caloric replacement by day seven post-injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TBI patients are at risk for other complications (eg, infection, gastrointestinal stress ulceration), which can be reduced by appropriate interventions. Other aspects of the general medical care of the trauma patient are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31066?source=see_link\">",
"     \"Overview of inpatient management in the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated intracranial pressure (ICP) is associated with increased mortality and worsened outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. While ICP monitoring is central to the management of patients with severe head injury, there have been no large randomized trials examining the effect of ICP monitoring and treatment on outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific measures regarding ICP management in the setting of TBI are discussed here. The evaluation and management of elevated ICP in other settings is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Diagnosis and initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several approaches are used in the intensive care setting to prevent and treat elevated ICP. Simple techniques should be instituted as soon as possible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head of bed elevation to 30 degrees",
"     </li>",
"     <li>",
"      Optimization of venous drainage: keeping the neck in neutral position, loosening neck braces if too tight",
"     </li>",
"     <li>",
"      Monitoring central venous pressure and avoiding excessive hypervolemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for ICP monitoring in TBI are a GCS score &le;8 and an abnormal CT scan showing evidence of mass effect from lesions such as hematomas, contusions, or swelling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/68\">",
"     68",
"    </a>",
"    ]. ICP monitoring in severe TBI patients with a normal CT scan may be indicated if two of the following features are present: age &gt;40 years; motor posturing; systolic BP &lt;90 mmHg. A ventricular catheter connected to a strain gauge transducer is the most accurate and cost-effective method of ICP monitoring and has the therapeutic advantage of allowing for CSF drainage to treat rises in ICP (",
"    <a class=\"graphic graphic_figure graphicRef56391 \" href=\"mobipreview.htm?27/61/28625\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/68\">",
"     68",
"    </a>",
"    ]. Other monitor types are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Types of monitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most guidelines and clinical protocols recommend that treatment for elevated ICP should be initiated when ICP rises above 20 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/69\">",
"     69",
"    </a>",
"    ]. Ventricular drainage is generally attempted first. CSF should be removed at a rate of approximately 1 to 2",
"    <span class=\"nowrap\">",
"     mL/minute,",
"    </span>",
"    for two to three minutes at a time, with intervals of two to three minutes in between until a satisfactory ICP has been achieved (ICP &lt;20 mmHg) or until CSF is no longer easily obtained. Slow removal can also be accomplished by passive gravitational drainage through the ventriculostomy.",
"   </p>",
"   <p>",
"    If ICP remains elevated, other targeted interventions include osmotic therapy, hyperventilation, and sedation. In refractory cases, barbiturate coma, induced hypothermia, and decompressive craniectomy may be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Osmotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravascular injection of hyperosmolar agents creates an osmolar gradient, drawing water across the blood-brain barrier. This leads to a decrease in interstitial volume and a decrease in ICP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       Mannitol",
"      </a>",
"      is the agent used most consistently to achieve ICP control in various settings, and it has also been shown to improve cerebral blood flow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/67,71-74\">",
"       67,71-74",
"      </a>",
"      ]. Mannitol is administered in boluses of 0.25 to 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      every four to six hours as needed. Monitoring of serum osmolality (maintained &lt;320",
"      <span class=\"nowrap\">",
"       mMol/L),",
"      </span>",
"      fluid balance, renal function, and electrolytes is required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H30#H30\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Mannitol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertonic saline is being used increasingly in this setting, but with varying volumes and tonicity (3 to 23.4 percent) and either as a bolus or continuous infusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. Two small studies compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      and hypertonic saline in patients with TBI:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study, nine patients received two treatments each of 200 mL 20 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      and 100 mL of 7.5 percent saline with 6 percent dextran-70 solution (HSD) in a random order [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/77\">",
"       77",
"      </a>",
"      ]. Median ICP reductions were greater with HSD than mannitol infusion (13 versus 7.5 mmHg).",
"     </li>",
"     <li>",
"      In another study, 20 patients were randomly assigned treatment with either 20 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      or 7.5 percent hypertonic saline solution, each given as a dose of 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/78\">",
"       78",
"      </a>",
"      ]. The mean number and duration of recurrent elevated ICP episodes were higher in patients treated with mannitol than with hypertonic saline.",
"     </li>",
"     <li>",
"      Clinical outcomes were not a focus of either of these studies. Further work is required to clarify what role hypertonic saline infusion has in the management of elevated ICP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/67,79\">",
"       67,79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hyperventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with severe TBI are sedated and artificially ventilated during the first several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/80\">",
"     80",
"    </a>",
"    ]. Regarding ICP management, control of ventilation helps prevent increases in intrathoracic pressure that may elevate central venous pressures and impair cerebral venous drainage.",
"   </p>",
"   <p>",
"    Hyperventilation can be used to reduce ICP. With hyperventilation, PaCO2 decreases thereby leading to cerebral vasoconstriction, which then results in decreased cerebral blood volume and ICP. However, hyperventilation-induced vasoconstriction may also cause secondary ischemia and may thereby worsen outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Hyperventilation can also increase extracellular lactate and glutamate levels that may contribute to secondary brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/84\">",
"     84",
"    </a>",
"    ]. In one randomized study, patients hyperventilated to a PaCO2 of 25 mmHg for five days had a worse clinical outcome than nonhyperventilated controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these competing concerns, guidelines recommend avoiding hyperventilation, especially in the acute phase (the first 24 to 48 hours) following TBI. Mild to moderate hyperventilation can be considered at later stages, but PaCO2 of less than 30 mmHg should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/86\">",
"     86",
"    </a>",
"    ]. Multimodality monitoring of cerebral oxygenation and metabolism (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Advanced neuromonitoring'",
"    </a>",
"    below) should also be used where available with therapeutic hyperventilation to monitor its effects and prevent ischemic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/82,83,87\">",
"     82,83,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sedative medications and pharmacological paralysis are often used in patients with severe head injury and elevated ICP. The rationale is that appropriate sedation may lower ICP by reducing metabolic demand. Sedation may also ameliorate ventilator asynchrony and blunt sympathetic responses of hypertension and tachycardia. These possible beneficial effects are counterbalanced by the potential for these drugs to cause hypotension and cerebral vasodilation that in turn may aggravate cerebral hypoperfusion and elevate ICP.",
"   </p>",
"   <p>",
"    Barbiturate coma has been used traditionally in this setting. However, there is little clinical data to support its use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 73 patients with severe TBI,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/31/4601?source=see_link\">",
"       pentobarbital",
"      </a>",
"      coma was associated with more effective ICP control compared to control treatment, but not improved 30-day mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/63/1015?source=see_link\">",
"       Thiopental",
"      </a>",
"      was compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/31/4601?source=see_link\">",
"       pentobarbital",
"      </a>",
"      in a small study of 44 patients with TBI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/89\">",
"       89",
"      </a>",
"      ]. While thiopental appeared more effective in terms of ICP control, conclusions drawn from this study are limited by its small size and an imbalance in baseline CT characteristics in the treatment groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, high-dose barbiturates often cause hypotension necessitating treatment with pressor agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/90\">",
"     90",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/31/4601?source=see_link\">",
"     Pentobarbital",
"    </a>",
"    remains a treatment option for elevated ICP refractory to other therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/91\">",
"     91",
"    </a>",
"    ]. A loading dose of 5 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is given as a bolus, followed by 1 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour. Continuous EEG monitoring is used, with the pentobarbital infusion titrated to produce a burst-suppression pattern.",
"   </p>",
"   <p>",
"    We prefer to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    at our institution because of its short duration of action that allows intermittent clinical neurologic assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/92\">",
"     92",
"    </a>",
"    ]. Anecdotally, propofol sedation can produce ICP reductions. Propofol also has putative neuroprotective effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/93\">",
"     93",
"    </a>",
"    ]. In one trial, propofol appeared to be associated with better ICP control and a trend toward better outcomes compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/94\">",
"     94",
"    </a>",
"    ]. However, some reports suggest that patients with TBI are at particular risk of developing the rare, but potentially fatal propofol infusion syndrome (severe metabolic acidosis, rhabdomyolysis, hyperkalemia, renal failure, and cardiovascular collapse) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. As a result, it is suggested that when used in TBI, the infusion rate of propofol not exceed 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour and that patients be monitored for ECG changes, lactic acidosis, and elevations in creatinine kinase and myoglobin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=see_link&amp;anchor=H7#H7\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\", section on 'Available agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other sedative agents may also be used, although none have been well studied in patients with severe TBI. These may include benzodiazepines or opiates (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) individually or in combination with barbiturates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuromuscular blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/91,97,98\">",
"     91,97,98",
"    </a>",
"    ]. A systematic review of trials of sedative agents in this setting found no convincing evidence to support the use of one agent over another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/99\">",
"     99",
"    </a>",
"    ]. However, high bolus doses of opioids were found to cause transient increases in intracranial pressure, which may warrant avoidance of that treatment approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of clinical trial data to support the use of any specific protocol, we suggest that the use of sedation be individualized according to specific clinical circumstances and that the choice of agent(s) be similarly individualized, considering also the specific institutional expertise. Monitoring of cerebral perfusion pressure is advised (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Cerebral perfusion pressure'",
"    </a>",
"    below) to evaluate the somewhat unpredictable effects of these agents on blood pressure and ICP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cerebral perfusion pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Through autoregulation, the normal cerebral vasculature maintains an adequate cerebral blood flow (CBF) across a wide range (50 to 150 mmHg) of mean arterial blood pressure (MAP). Cerebral autoregulation is disrupted in about a third of patients with severe TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. In these patients, a rise in MAP can lead to elevated ICP due to increased cerebral blood volume and hyperemia, while drops in MAP may be associated with hypoperfusion and ischemia. Patients with impaired cerebral autoregulation are described as \"pressure-passive\".",
"   </p>",
"   <p>",
"    While optimization of CBF is a foundation of TBI treatment, bedside measurement of CBF is not easily obtained. Cerebral perfusion pressure (CPP), the difference between the mean arterial pressure (MAP) and the intracranial pressure: CPP = MAP - ICP, is a surrogate measure. Episodes of hypotension (low MAP), raised ICP,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low CPP are associated with secondary brain injury and worse clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/18,19,103\">",
"     18,19,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An early approach to induce hypertension to target CPP &gt;70 mmHg using volume expansion and vasopressor agents appeared to reduce mortality and morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. However, subsequent studies have suggested that this strategy does not improve outcome and rather risks severe extra-cerebral complications such as acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. According to guidelines published in 2007, the recommended CPP target is 60 mmHg, avoiding levels below 50 mmHg and above 70 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. In children these thresholds may be lower, 40 to 65 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/111\">",
"     111",
"    </a>",
"    ]. Efforts to optimize CPP should first treat and maintain ICP at low levels when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/112\">",
"     112",
"    </a>",
"    ]. This may have a more substantial effect on CBF and obviate the use of fluids and inotropic agents. Patients with more severely impaired autoregulation in particular may be more likely to respond to efforts to lower ICP than to hypertensive-focused CPP therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antiepileptic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the incidence of early post-traumatic seizures (within the first week or two) is about 6 to 10 percent but may be as high as 30 percent in patients with severe TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/113-115\">",
"     113-115",
"    </a>",
"    ]. In addition, case series suggest that about 15 to 25 percent of patients with coma and severe head injury will have nonconvulsive seizures identified on continuous monitoring with electroencephalography (EEG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. However, the clinical significance of clinically silent electrographic seizures and whether they should be treated is unclear.",
"   </p>",
"   <p>",
"    The use of antiepileptic drugs (AEDs) in the acute management of TBI has been shown to reduce the incidence of early seizures, but does not prevent the later development of epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Reasons to prevent early seizures include the risk of status epilepticus, which has a high fatality rate in this setting, and the potential of convulsions to aggravate a systemic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/115\">",
"     115",
"    </a>",
"    ]. In addition, recurrent seizures may increase cerebral blood flow and could thereby increase ICP. Another potential concern is that seizures place a metabolic demand on damaged brain tissue and may aggravate secondary brain injury.",
"   </p>",
"   <p>",
"    Based upon the available information, we use the following approach to seizure management in patients with severe TBI:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use a seven-day course of prophylactic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      or valproic acid",
"     </li>",
"     <li>",
"      Do not use AED prophylaxis long-term",
"     </li>",
"     <li>",
"      Consider EEG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      EEG monitoring in patients with coma",
"     </li>",
"     <li>",
"      Treat both clinical and electrographic-only seizures with AEDs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Post-traumatic seizures and epilepsy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4935?source=see_link\">",
"     \"Post-traumatic seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Temperature management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever worsens outcome after stroke and probably severe head injury, presumably by aggravating secondary brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/18\">",
"     18",
"    </a>",
"    ]. Current approaches emphasize maintaining normothermia through the use of antipyretic medications, surface cooling devices, or even endovascular temperature management catheters. However, this approach has not been systematically tested with regard to clinical outcome. Similarly noninduced hypothermia has been associated with an increase in mortality after TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/119\">",
"     119",
"    </a>",
"    ], but the efficacy of efforts to avoid this complication have not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Induced hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induced hypothermia has been a proposed treatment for TBI based upon its potential to reduce ICP as well as to provide neuroprotection and prevent secondary brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/120\">",
"     120",
"    </a>",
"    ]. Induced hypothermia has been shown to be effective in improving neurologic outcome after ventricular fibrillation cardiac arrest. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=see_link&amp;anchor=H7#H7\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\", section on 'Therapeutic (induced) hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of 22 randomized controlled trials of mild-to-moderate hypothermia (32 to 35&ordm;C) following TBI noted a small but significant decrease in the risk of death (RR 0.76, 95% CI 0.60-0.97) or poor neurologic outcome (RR 0.69, 95% CI 0.55-0.86) among more than 1300 patients treated, but noted that significant benefit was seen only in low quality trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/121\">",
"     121",
"    </a>",
"    ]. Other systematic reviews and meta-analyses found similar but more borderline benefits for death and neurologic outcome as well as an increased risk for pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/120,122-124\">",
"     120,122-124",
"    </a>",
"    ]. Substantial variability among studies in the depth and duration of hypothermia, as well as the rate of rewarming limit the ability to draw conclusions from these studies. A subsequently published trial examined the potential benefit of hypothermia when initiated within two to five hours of TBI in a selected group of younger patients and found no benefit of treatment on mortality or neurologic outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A trial of hypothermia therapy in children with TBI showed no improvement in neurologic outcomes and a nonsignificant increase in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/126\">",
"     126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44633?source=see_link&amp;anchor=H30#H30\">",
"     \"Elevated intracranial pressure in children\", section on 'Hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the uncertainties surrounding its appropriate use, therapeutic hypothermia treatment should be limited to clinical trials, or to patients with elevated ICP refractory to other therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/121,127,128\">",
"     121,127,128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Glucose management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia is associated with worsened outcome in a variety of neurologic conditions including severe TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/129-131\">",
"     129-131",
"    </a>",
"    ]. In a retrospective cohort study of 77 patients with severe traumatic brain injury, hyperglycemia (blood glucose &ge;170",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [9.4",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    at the time of ICU admission was an independent predictor of a poor GCS score five days later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This has been presumed to be at least in part related to aggravation of secondary brain injury. Several mechanisms for this are proposed including increased tissue acidosis from anaerobic metabolism, free radical generation, and increased blood brain barrier permeability. Increased use of insulin infusions to maintain tight glucose control in critically ill patients has been studied, but the optimal glucose target and best treatment regimen is uncertain. One case series using cerebral microdialysis found that tight glycemic control was associated with reduced cerebral glucose availability and elevated",
"    <span class=\"nowrap\">",
"     lactate/pyruvate",
"    </span>",
"    ratio which in turn was associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, avoidance of both hypo- and hyperglycemia is appropriate, but further studies are needed to clarify the optimal serum glucose target range and duration of therapy. To avoid extremes of very high or low blood glucose levels, a broad target range of up to 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or possibly even 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7527255\">",
"    <span class=\"h2\">",
"     Hemostatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of patients with severe TBI develop a coagulopathy, which is associated with an increased risk of hemorrhage enlargement, poor neurologic outcomes and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/133-137\">",
"     133-137",
"    </a>",
"    ]. The coagulopathy may result from existing patient medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or antiplatelet agents. Acute TBI is also thought to produce a coagulopathy through the systemic release of tissue factor and brain phospholipids into the circulation leading to inappropriate intravascular coagulation and a consumptive coagulopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/138\">",
"     138",
"    </a>",
"    ]. Coagulation parameters should be measured in the emergency department in all patients with severe TBI and efforts to correct any identified coagulopathy should begin immediately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      may be managed with prothrombin complex concentrate (PCC), fresh frozen plasma (FFP),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vitamin K as recommended for patients with warfarin-associated intracerebral hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with thrombocytopenia, many centers choose to maintain a platelet count &gt; 75,000 with platelet transfusions if necessary. The utility of platelet transfusions in TBI patients who arrive on antiplatelet medications is not known. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link&amp;anchor=H10#H10\">",
"       \"Use of blood products in the critically ill\", section on 'Platelets'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for hemostatic therapy in other categories of patients with severe TBI are limited by lack of evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/139\">",
"     139",
"    </a>",
"    ]. When a coagulopathy is identified, it is reasonable to use FFP, PCC,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin K as for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -reversal. A reasonable, if somewhat arbitrary target it an INR &lt; 1.4. A phase II dose-escalation clinical trial of recombinant factor VIIa in TBI patients demonstrated a non-significant trend towards limiting hematoma expansion but no mortality benefit, although this was not directed exclusively at patients with TBI-related INR elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/140\">",
"     140",
"    </a>",
"    ]. Similarly hemostatic therapy has not been shown to be of overall benefit in patients with nontraumatic intracerebral hemorrhage, including those that are warfarin-associated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=see_link&amp;anchor=H22#H22\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Hemostatic therapy'",
"    </a>",
"    .) There is no evidence that hemostatic therapy benefits noncoagulopathic patients with severe TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/141,142\">",
"     141,142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coagulopathy associated with trauma is discussed in detail separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23242?source=see_link\">",
"     \"Coagulopathy associated with trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glucocorticoid therapy following head trauma was found to be harmful rather than beneficial in a large trial of patients with moderate to severe TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/143\">",
"     143",
"    </a>",
"    ]. More than 10,000 patients within eight hours of presentation were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or to placebo. Treated patients had increased mortality at two weeks (21 versus 18 percent; RR 1.18) and at six-month follow-up (26 versus 22 percent; RR 1.15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Neuroprotective treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a wide range of agents targeting various aspects of the TBI injury cascade has been tested in clinical trials. To date, no neuroprotective agents or strategies (including induced hypothermia) have been shown to produce improved outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/45\">",
"     45",
"    </a>",
"    ]. Based on a positive phase II studies, intravenous progesterone is being tested in a pivotal phase III clinical trial as a neuroprotective agent for severe head injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. Other agents being investigated include magnesium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/147\">",
"     147",
"    </a>",
"    ], citicoline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/148\">",
"     148",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/149\">",
"     149",
"    </a>",
"    ] among others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythropoietin has been postulated to have neuroprotective effects. In a retrospective case control study in 267 patients with severe TBI, matched for both GCS and severity of systemic injuries, in-hospital mortality was lower among 89 patients treated with erythropoietin compared with 178 control patients (8 versus 24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/151\">",
"     151",
"    </a>",
"    ]. A number of confounding factors may have biased these results, which require prospective validation in a clinical trial before such treatment can be recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/152\">",
"     152",
"    </a>",
"    ]. Such a trial is ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ADVANCED NEUROMONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to supplement ICP monitoring, several technologies have recently been developed for the treatment of severe TBI. These techniques allow for the measurement of cerebral physiologic and metabolic parameters related to oxygen delivery, cerebral blood flow, and metabolism with the goal of improving the detection and management of secondary brain injury.",
"   </p>",
"   <p>",
"    Current monitoring techniques include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jugular venous oximetry: retrograde cannulation of the internal jugular vein that allows measurement of oxygen saturation in the blood exiting the brain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/153\">",
"       153",
"      </a>",
"      ]. Normal jugular venous oxygen saturation (SjVO2) is about 60 percent. SjVO2 &lt;50 percent for 10 minutes is considered an \"ischemic desaturation\" and is associated with impaired CPP and worsened outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/154\">",
"       154",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brain tissue oxygen tension (PbtO2) monitoring: intraparenchymal oxygen electrode placed in a manner similar to a fiberoptic ICP probe that measures PbtO2 in the white matter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/155\">",
"       155",
"      </a>",
"      ]. Normal PbtO2 is &gt;20 mmHg; duration and depth of PbtO2 below 15 mmHg is associated with worsened outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/154\">",
"       154",
"      </a>",
"      ]. One case series used oxygen supplementation to maintain PbtO2 above 25 mmHg and found better outcomes compared with historical controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/156\">",
"       156",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cerebral microdialysis: intraparenchymal probe placed similarly to a PbtO2 probe that allows measurement of extracellular glucose, lactate, pyruvate, glutamate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/157\">",
"       157",
"      </a>",
"      ]. A lactate:pyruvate ratio &gt;40 is suggestive of anaerobic metabolism, which is believed to exacerbate secondary brain injury.",
"     </li>",
"     <li>",
"      Thermal diffusion flowmetry: intraparenchymal probe placed similarly to a PbtO2 probe that allows continuous measurement of CBF, usually in the white matter. Correlation with CBF from neuroimaging and outcome data is very preliminary at present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational data suggests that these monitoring tools provide unique information that may help to individualize severe head injury management for patients. Clinical trials are currently in the planning phases for use of these multi-modality advanced neuromonitoring approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome from severe head injury is dependent on a range of factors including baseline patient characteristics, severity of TBI, and the occurrence of medical complications and secondary brain insults. Specific negative outcome predictors that have been identified from these factors include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/13,16-18,45,65,137,158-162\">",
"     13,16-18,45,65,137,158-162",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GCS at presentation (especially the GCS motor score)",
"     </li>",
"     <li>",
"      CT findings (subarachnoid hemorrhage, cisternal effacement, midline shift)",
"     </li>",
"     <li>",
"      Pupillary function",
"     </li>",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Associated injuries and complications",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Hypoxemia",
"     </li>",
"     <li>",
"      Pyrexia",
"     </li>",
"     <li>",
"      Elevated ICP",
"     </li>",
"     <li>",
"      Reduced CPP",
"     </li>",
"     <li>",
"      Bleeding diathesis (low platelet count, abnormal coagulation parameters)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While some have attempted to develop outcome prediction models to guide decisions about withholding early treatment, the heterogeneity of severe head injury makes this difficult to apply to clinical decision making in individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/159\">",
"     159",
"    </a>",
"    ]. Thus, except in the most extreme cases, a trial of early aggressive neurosurgical and neurocritical care management, including surgical removal of evacuable lesions and ICP monitoring, should be undertaken.",
"   </p>",
"   <p>",
"    Cohort studies have suggested that patients with severe head injury (GCS &le;8) have about a 30 percent risk of death. At least one cohort study found that survivors of TBI continue to have a substantially increased risk of mortality for at least 13 years after hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only about 25 percent of survivors achieve long-term functional independence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/65,158,164\">",
"     65,158,164",
"    </a>",
"    ]. Approximately 5 to 15 percent of patients with severe TBI are discharged from acute care in a vegetative state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/158,164,165\">",
"     158,164,165",
"    </a>",
"    ]. Only half of these patients regain consciousness over the next year and virtually all of these patients remain severely disabled. Outcomes are somewhat better for those in the minimally conscious state. The persistent vegetative and minimally conscious states are described separately. The use of prognostic indicators for these outcomes is better defined for hypoxic-ischemic brain injury than for TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/166\">",
"     166",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=see_link&amp;anchor=H4#H4\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\", section on 'Persistent vegetative state'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=see_link&amp;anchor=H5#H5\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\", section on 'Minimally conscious state'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    (starting at 100 mg twice daily) in 184 patients admitted to inpatient rehabilitation in a vegetative or minimally conscious state after severe TBI found that amantadine treatment was associated with accelerated recovery during the four week active treatment phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/2/35882/abstract/167\">",
"     167",
"    </a>",
"    ]. Rates of improvement subsequently slowed after treatment withdrawal in the amantadine group and at week six, disability scores in the two groups were similar. Further study is needed to determine a benefit for amantadine on long term prognosis and its role in the treatment of patients with severe TBI. The mechanism of action for amantadine&rsquo;s putative effect is unclear; it is speculated that antagonism of N-methyl-D-aspartate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    indirect agonsim of dopamine may be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"       \"Patient information: Closed head injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe traumatic brain injury (TBI) are most optimally managed in a specialized neurotrauma center with neurosurgical and neurocritical care support and the use of guidelines-based standardized protocols.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of hypoxia (PaO2 &lt;60 mmHg) and hypotension (systolic BP &lt;90 mmHg) are priorities in the management of patients with severe TBI beginning with their prehospital care. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial evaluation and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergency department evaluation should include frequent clinical neurologic assessments and a computed tomography (CT) scan of the head.",
"      <br/>",
"      <br/>",
"      When impending herniation due to elevated intracranial pressure (ICP) is suspected in a patient with severe TBI, we recommend treatment with head of bed elevation and intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      pending the results of the CT and measurement of intracranial pressure (ICP) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Emergency department'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical evacuation of epidural, subdural, and intracerebral hematomas are performed based upon blood volume and associated mass effect, in conjunction with the patient's neurologic status. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend ventriculostomy placement with ICP monitoring in patients with severe TBI and an abnormal CT scan showing evidence of mass effect from lesions such as hematomas, contusions or swelling. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Intracranial pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment of elevated ICP to target pressures below 20 mmHg (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Appropriate first measures include removal of cerebrospinal fluid through the ventriculostomy, head of bed elevation, followed by osmotic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis and initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Osmotic therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with elevated ICP refractory to initial therapy, treatment options include hyperventilation, barbiturate coma, induced hypothermia, and decompressive craniectomy. Hyperventilation should be avoided in the first 24 to 48 hours and should not exceed PaCO2 &lt;30 mmHg. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hyperventilation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Sedation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Temperature management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Decompressive craniectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend using normal saline to maintain euvolemia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'General medical care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerebral perfusion pressure (CPP) (the difference between mean arterial pressure and ICP) should be continuously assessed. The suggested CPP target is 60 mmHg, avoiding CPP &gt;70 mmHg and &lt;50 mmHg, which should be achieved by optimizing ICP first and then MAP (with volume expansion, pressors) second. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Cerebral perfusion pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend short-term (one week) use of antiepileptic drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ) for the prevention of early seizures (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Antiepileptic drugs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4935?source=see_link\">",
"       \"Post-traumatic seizures and epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that fever and hyperglycemia be avoided for their potential to exacerbate secondary neurologic injury. Coagulopathy should be corrected to maintain an INR &lt; 1.4 and a platelet count &gt;",
"      <span class=\"nowrap\">",
"       75,000/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H14\">",
"       'General medical care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Temperature management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Glucose management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7527255\">",
"       'Hemostatic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend thromboprophylaxis for the prevention of venous thromboembolism (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The use and timing of antithrombotic agents is individualized based upon an assessment of the competing risks of venous thrombosis and intracranial hemorrhage expansion. Patients not receiving antithrombotic therapy should wear pneumatic compression stockings. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'General medical care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using glucocorticoids for the management of patients with severe TBI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of sedative medications should be individualized. Options include barbiturates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , benzodiazepines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    . These can be used individually, in combination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with neuromuscular blockade. Blood pressure, ICP, and CPP should be monitored as these are somewhat unpredictably affected by these medications. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Sedation'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/1\">",
"      Rutland-Brown W, Langlois JA, Thomas KE, Xi YL. Incidence of traumatic brain injury in the United States, 2003. J Head Trauma Rehabil 2006; 21:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/2\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. Introduction. J Neurotrauma 2007; 24 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/3\">",
"      Maas AI, Dearden M, Teasdale GM, et al. EBIC-guidelines for management of severe head injury in adults. European Brain Injury Consortium. Acta Neurochir (Wien) 1997; 139:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/4\">",
"      Newcombe R, Merry G. The management of acute neurotrauma in rural and remote locations: A set of guidelines for the care of head and spinal injuries. J Clin Neurosci 1999; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/5\">",
"      Adelson PD, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 1: Introduction. Pediatr Crit Care Med 2003; 4:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/6\">",
"      Patel HC, Bouamra O, Woodford M, et al. Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study. Lancet 2005; 366:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/7\">",
"      Suarez JI, Zaidat OO, Suri MF, et al. Length of stay and mortality in neurocritically ill patients: impact of a specialized neurocritical care team. Crit Care Med 2004; 32:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/8\">",
"      Thillai M. Neurosurgical units working beyond safe capacity. BMJ 2000; 320:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/9\">",
"      Varelas PN, Conti MM, Spanaki MV, et al. The impact of a neurointensivist-led team on a semiclosed neurosciences intensive care unit. Crit Care Med 2004; 32:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/10\">",
"      Visca A, Faccani G, Massaro F, et al. Clinical and neuroimaging features of severely brain-injured patients treated in a neurosurgical unit compared with patients treated in peripheral non-neurosurgical hospitals. Br J Neurosurg 2006; 20:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/11\">",
"      Brown JB, Stassen NA, Cheng JD, et al. Trauma center designation correlates with functional independence after severe but not moderate traumatic brain injury. J Trauma 2010; 69:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/12\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. I. Blood pressure and oxygenation. J Neurotrauma 2007; 24 Suppl 1:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/13\">",
"      McHugh GS, Engel DC, Butcher I, et al. Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/14\">",
"      Silverston P. Pulse oximetry at the roadside: a study of pulse oximetry in immediate care. BMJ 1989; 298:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/15\">",
"      Stocchetti N, Furlan A, Volta F. Hypoxemia and arterial hypotension at the accident scene in head injury. J Trauma 1996; 40:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/16\">",
"      Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma 1993; 34:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/17\">",
"      Manley G, Knudson MM, Morabito D, et al. Hypotension, hypoxia, and head injury: frequency, duration, and consequences. Arch Surg 2001; 136:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/18\">",
"      Andrews PJ, Sleeman DH, Statham PF, et al. Predicting recovery in patients suffering from traumatic brain injury by using admission variables and physiological data: a comparison between decision tree analysis and logistic regression. J Neurosurg 2002; 97:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/19\">",
"      Clifton GL, Miller ER, Choi SC, Levin HS. Fluid thresholds and outcome from severe brain injury. Crit Care Med 2002; 30:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/20\">",
"      Winchell RJ, Hoyt DB. Endotracheal intubation in the field improves survival in patients with severe head injury. Trauma Research and Education Foundation of San Diego. Arch Surg 1997; 132:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/21\">",
"      Rudehill A, Bellander BM, Weitzberg E, et al. Outcome of traumatic brain injuries in 1,508 patients: impact of prehospital care. J Neurotrauma 2002; 19:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/22\">",
"      Davis DP, Peay J, Sise MJ, et al. Prehospital airway and ventilation management: a trauma score and injury severity score-based analysis. J Trauma 2010; 69:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/23\">",
"      Bernard SA, Nguyen V, Cameron P, et al. Prehospital rapid sequence intubation improves functional outcome for patients with severe traumatic brain injury: a randomized controlled trial. Ann Surg 2010; 252:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/24\">",
"      Davis DP, Hoyt DB, Ochs M, et al. The effect of paramedic rapid sequence intubation on outcome in patients with severe traumatic brain injury. J Trauma 2003; 54:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/25\">",
"      Davis DP, Fakhry SM, Wang HE, et al. Paramedic rapid sequence intubation for severe traumatic brain injury: perspectives from an expert panel. Prehosp Emerg Care 2007; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/26\">",
"      Cooper DJ, Myles PS, McDermott FT, et al. Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial. JAMA 2004; 291:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/27\">",
"      Bulger EM, May S, Brasel KJ, et al. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA 2010; 304:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/28\">",
"      SAFE Study Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Service, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/29\">",
"      Servadei F, Murray GD, Penny K, et al. The value of the \"worst\" computed tomographic scan in clinical studies of moderate and severe head injury. European Brain Injury Consortium. Neurosurgery 2000; 46:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/30\">",
"      Chang EF, Meeker M, Holland MC. Acute traumatic intraparenchymal hemorrhage: risk factors for progression in the early post-injury period. Neurosurgery 2006; 58:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/31\">",
"      Oertel M, Kelly DF, McArthur D, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg 2002; 96:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/32\">",
"      Narayan RK, Maas AI, Servadei F, et al. Progression of traumatic intracerebral hemorrhage: a prospective observational study. J Neurotrauma 2008; 25:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/33\">",
"      Thomas BW, Mejia VA, Maxwell RA, et al. Scheduled repeat CT scanning for traumatic brain injury remains important in assessing head injury progression. J Am Coll Surg 2010; 210:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/34\">",
"      Connon FF, Namdarian B, Ee JL, et al. Do routinely repeated computed tomography scans in traumatic brain injury influence management? A prospective observational study in a level 1 trauma center. Ann Surg 2011; 254:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/35\">",
"      Kaups KL, Davis JW, Parks SN. Routinely repeated computed tomography after blunt head trauma: does it benefit patients? J Trauma 2004; 56:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/36\">",
"      Huang AP, Lee CW, Hsieh HJ, et al. Early parenchymal contrast extravasation predicts subsequent hemorrhage progression, clinical deterioration, and need for surgery in patients with traumatic cerebral contusion. J Trauma 2011; 71:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/37\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute epidural hematomas. Neurosurgery 2006; 58:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/38\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery 2006; 58:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/39\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of posterior fossa mass lesions. Neurosurgery 2006; 58:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/40\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of traumatic parenchymal lesions. Neurosurgery 2006; 58:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/41\">",
"      Surgical management of penetrating brain injury. J Trauma 2001; 51:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/42\">",
"      Antibiotic prophylaxis for penetrating brain injury. J Trauma 2001; 51:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/43\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of depressed cranial fractures. Neurosurgery 2006; 58:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/44\">",
"      Compagnone C, Murray GD, Teasdale GM, et al. The management of patients with intradural post-traumatic mass lesions: a multicenter survey of current approaches to surgical management in 729 patients coordinated by the European Brain Injury Consortium. Neurosurgery 2005; 57:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/45\">",
"      Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008; 7:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/46\">",
"      Citerio G, Andrews PJ. Refractory elevated intracranial pressure: intensivist's role in solving the dilemma of decompressive craniectomy. Intensive Care Med 2007; 33:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/47\">",
"      M&uuml;nch E, Horn P, Sch&uuml;rer L, et al. Management of severe traumatic brain injury by decompressive craniectomy. Neurosurgery 2000; 47:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/48\">",
"      Polin RS, Shaffrey ME, Bogaev CA, et al. Decompressive bifrontal craniectomy in the treatment of severe refractory posttraumatic cerebral edema. Neurosurgery 1997; 41:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/49\">",
"      Jiang JY, Xu W, Li WP, et al. Efficacy of standard trauma craniectomy for refractory intracranial hypertension with severe traumatic brain injury: a multicenter, prospective, randomized controlled study. J Neurotrauma 2005; 22:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/50\">",
"      Ho KM, Honeybul S, Lind CR, et al. Cost-effectiveness of decompressive craniectomy as a lifesaving rescue procedure for patients with severe traumatic brain injury. J Trauma 2011; 71:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/51\">",
"      Hutchinson PJ, Corteen E, Czosnyka M, et al. Decompressive craniectomy in traumatic brain injury: the randomized multicenter RESCUEicp study (www.RESCUEicp.com). Acta Neurochir Suppl 2006; 96:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/52\">",
"      Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med 2011; 364:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/53\">",
"      Servadei F. Clinical value of decompressive craniectomy. N Engl J Med 2011; 364:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/54\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. V. Deep vein thrombosis prophylaxis. J Neurotrauma 2007; 24 Suppl 1:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/55\">",
"      Reiff DA, Haricharan RN, Bullington NM, et al. Traumatic brain injury is associated with the development of deep vein thrombosis independent of pharmacological prophylaxis. J Trauma 2009; 66:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/56\">",
"      Norwood SH, Berne JD, Rowe SA, et al. Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury. J Trauma 2008; 65:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/57\">",
"      Norwood SH, McAuley CE, Berne JD, et al. Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. Arch Surg 2002; 137:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/58\">",
"      Salottolo K, Offner P, Levy AS, et al. Interrupted pharmocologic thromboprophylaxis increases venous thromboembolism in traumatic brain injury. J Trauma 2011; 70:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/59\">",
"      Koehler DM, Shipman J, Davidson MA, Guillamondegui O. Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage. J Trauma 2011; 70:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/60\">",
"      Scudday T, Brasel K, Webb T, et al. Safety and efficacy of prophylactic anticoagulation in patients with traumatic brain injury. J Am Coll Surg 2011; 213:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/61\">",
"      Rapp RP, Young B, Twyman D, et al. The favorable effect of early parenteral feeding on survival in head-injured patients. J Neurosurg 1983; 58:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/62\">",
"      Perel P, Yanagawa T, Bunn F, et al. Nutritional support for head-injured patients. Cochrane Database Syst Rev 2006; :CD001530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/63\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. XII. Nutrition. J Neurotrauma 2007; 24 Suppl 1:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/64\">",
"      Marmarou, A, Anderson, L, Ward, J, et al. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. J Neurosurg 1991; 75:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/65\">",
"      Schreiber MA, Aoki N, Scott BG, Beck JR. Determinants of mortality in patients with severe blunt head injury. Arch Surg 2002; 137:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/66\">",
"      Lundberg N, Troupp H, Lorin H. Continuous recording of the ventricular-fluid pressure in patients with severe acute traumatic brain injury. A preliminary report. J Neurosurg 1965; 22:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/67\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma 2007; 24 Suppl 1:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/68\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. VI. Indications for intracranial pressure monitoring. J Neurotrauma 2007; 24 Suppl 1:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/69\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. VIII. Intracranial pressure thresholds. J Neurotrauma 2007; 24 Suppl 1:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/70\">",
"      Stocchetti N, Zanaboni C, Colombo A, et al. Refractory intracranial hypertension and \"second-tier\" therapies in traumatic brain injury. Intensive Care Med 2008; 34:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/71\">",
"      James HE. Methodology for the control of intracranial pressure with hypertonic mannitol. Acta Neurochir (Wien) 1980; 51:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/72\">",
"      McGraw CP, Howard G. Effect of mannitol on increased intracranial pressure. Neurosurgery 1983; 13:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/73\">",
"      Muizelaar JP, Wei EP, Kontos HA, Becker DP. Mannitol causes compensatory cerebral vasoconstriction and vasodilation in response to blood viscosity changes. J Neurosurg 1983; 59:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/74\">",
"      Sakowitz OW, Stover JF, Sarrafzadeh AS, et al. Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients. J Trauma 2007; 62:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/75\">",
"      Shackford SR, Bourguignon PR, Wald SL, et al. Hypertonic saline resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma 1998; 44:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/76\">",
"      Ware ML, Nemani VM, Meeker M, et al. Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: a preliminary study. Neurosurgery 2005; 57:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/77\">",
"      Battison C, Andrews PJ, Graham C, Petty T. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med 2005; 33:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/78\">",
"      Vialet R, Alban&egrave;se J, Thomachot L, et al. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Crit Care Med 2003; 31:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/79\">",
"      Bhardwaj A, Ulatowski JA. Hypertonic saline solutions in brain injury. Curr Opin Crit Care 2004; 10:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/80\">",
"      Vandromme MJ, Melton SM, Griffin R, et al. Intubation patterns and outcomes in patients with computed tomography-verified traumatic brain injury. J Trauma 2011; 71:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/81\">",
"      Stocchetti N, Maas AI, Chieregato A, van der Plas AA. Hyperventilation in head injury: a review. Chest 2005; 127:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/82\">",
"      Imberti R, Bellinzona G, Langer M. Cerebral tissue PO2 and SjvO2 changes during moderate hyperventilation in patients with severe traumatic brain injury. J Neurosurg 2002; 96:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/83\">",
"      Coles JP, Minhas PS, Fryer TD, et al. Effect of hyperventilation on cerebral blood flow in traumatic head injury: clinical relevance and monitoring correlates. Crit Care Med 2002; 30:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/84\">",
"      Marion DW, Puccio A, Wisniewski SR, et al. Effect of hyperventilation on extracellular concentrations of glutamate, lactate, pyruvate, and local cerebral blood flow in patients with severe traumatic brain injury. Crit Care Med 2002; 30:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/85\">",
"      Muizelaar JP, Marmarou A, Ward JD, et al. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg 1991; 75:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/86\">",
"      Diringer MN, Yundt K, Videen TO, et al. No reduction in cerebral metabolism as a result of early moderate hyperventilation following severe traumatic brain injury. J Neurosurg 2000; 92:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/87\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. XIV. Hyperventilation. J Neurotrauma 2007; 24 Suppl 1:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/88\">",
"      Eisenberg HM, Frankowski RF, Contant CF, et al. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg 1988; 69:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/89\">",
"      P&eacute;rez-B&aacute;rcena J, Llompart-Pou JA, Homar J, et al. Pentobarbital versus thiopental in the treatment of refractory intracranial hypertension in patients with traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12:R112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/90\">",
"      Roberts I. Barbiturates for acute traumatic brain injury. Cochrane Database Syst Rev 2000; :CD000033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/91\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. XI. Anesthetics, analgesics, and sedatives. J Neurotrauma 2007; 24 Suppl 1:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/92\">",
"      Skoglund K, Enblad P, Marklund N. Effects of the neurological wake-up test on intracranial pressure and cerebral perfusion pressure in brain-injured patients. Neurocrit Care 2009; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/93\">",
"      Rossaint J, Rossaint R, Weis J, et al. Propofol: neuroprotection in an in vitro model of traumatic brain injury. Crit Care 2009; 13:R61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/94\">",
"      Kelly DF, Goodale DB, Williams J, et al. Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial. J Neurosurg 1999; 90:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/95\">",
"      Otterspoor LC, Kalkman CJ, Cremer OL. Update on the propofol infusion syndrome in ICU management of patients with head injury. Curr Opin Anaesthesiol 2008; 21:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/96\">",
"      Sabsovich I, Rehman Z, Yunen J, Coritsidis G. Propofol infusion syndrome: a case of increasing morbidity with traumatic brain injury. Am J Crit Care 2007; 16:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/97\">",
"      Olivecrona M, Zetterlund B, Rodling-Wahlstr&ouml;m M, et al. Absence of electroencephalographic seizure activity in patients treated for head injury with an intracranial pressure-targeted therapy. J Neurosurg 2009; 110:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/98\">",
"      Adelson PD, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 9. Use of sedation and neuromuscular blockade in the treatment of severe pediatric traumatic brain injury. Pediatr Crit Care Med 2003; 4:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/99\">",
"      Roberts DJ, Hall RI, Kramer AH, et al. Sedation for critically ill adults with severe traumatic brain injury: a systematic review of randomized controlled trials. Crit Care Med 2011; 39:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/100\">",
"      Bouma GJ, Muizelaar JP. Cerebral blood flow, cerebral blood volume, and cerebrovascular reactivity after severe head injury. J Neurotrauma 1992; 9 Suppl 1:S333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/101\">",
"      Bouma GJ, Muizelaar JP, Bandoh K, Marmarou A. Blood pressure and intracranial pressure-volume dynamics in severe head injury: relationship with cerebral blood flow. J Neurosurg 1992; 77:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/102\">",
"      Muizelaar JP, Ward JD, Marmarou A, et al. Cerebral blood flow and metabolism in severely head-injured children. Part 2: Autoregulation. J Neurosurg 1989; 71:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/103\">",
"      Juul N, Morris GF, Marshall SB, Marshall LF. Intracranial hypertension and cerebral perfusion pressure: influence on neurological deterioration and outcome in severe head injury. The Executive Committee of the International Selfotel Trial. J Neurosurg 2000; 92:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/104\">",
"      Rosner MJ, Daughton S. Cerebral perfusion pressure management in head injury. J Trauma 1990; 30:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/105\">",
"      Robertson CS, Valadka AB, Hannay HJ, et al. Prevention of secondary ischemic insults after severe head injury. Crit Care Med 1999; 27:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/106\">",
"      Howells T, Elf K, Jones PA, et al. Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma. J Neurosurg 2005; 102:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/107\">",
"      Contant CF, Valadka AB, Gopinath SP, et al. Adult respiratory distress syndrome: a complication of induced hypertension after severe head injury. J Neurosurg 2001; 95:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/108\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. IX. Cerebral perfusion thresholds. J Neurotrauma 2007; 24 Suppl 1:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/109\">",
"      Elf K, Nilsson P, Ronne-Engstr&ouml;m E, et al. Cerebral perfusion pressure between 50 and 60 mm Hg may be beneficial in head-injured patients: a computerized secondary insult monitoring study. Neurosurgery 2005; 56:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/110\">",
"      Jaeger M, Dengl M, Meixensberger J, Schuhmann MU. Effects of cerebrovascular pressure reactivity-guided optimization of cerebral perfusion pressure on brain tissue oxygenation after traumatic brain injury. Crit Care Med 2010; 38:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/111\">",
"      Adelson PD, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 8. Cerebral perfusion pressure. Pediatr Crit Care Med 2003; 4:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/112\">",
"      Gr&auml;nde PO. The \"Lund Concept\" for the treatment of severe head trauma--physiological principles and clinical application. Intensive Care Med 2006; 32:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/113\">",
"      Temkin NR. Risk factors for posttraumatic seizures in adults. Epilepsia 2003; 44 Suppl 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/114\">",
"      Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia 2003; 44 Suppl 10:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/115\">",
"      Vespa PM, Nuwer MR, Nenov V, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg 1999; 91:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/116\">",
"      Ronne-Engstrom E, Winkler T. Continuous EEG monitoring in patients with traumatic brain injury reveals a high incidence of epileptiform activity. Acta Neurol Scand 2006; 114:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/117\">",
"      Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990; 323:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/118\">",
"      Schierhout G, Roberts I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury. Cochrane Database Syst Rev 2001; :CD000173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/119\">",
"      Konstantinidis A, Inaba K, Dubose J, et al. The impact of nontherapeutic hypothermia on outcomes after severe traumatic brain injury. J Trauma 2011; 71:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/120\">",
"      Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 2001; 344:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/121\">",
"      Sydenham E, Roberts I, Alderson P. Hypothermia for traumatic head injury. Cochrane Database Syst Rev 2009; :CD001048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/122\">",
"      McIntyre LA, Fergusson DA, H&eacute;bert PC, et al. Prolonged therapeutic hypothermia after traumatic brain injury in adults: a systematic review. JAMA 2003; 289:2992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/123\">",
"      Henderson WR, Dhingra VK, Chittock DR, et al. Hypothermia in the management of traumatic brain injury. A systematic review and meta-analysis. Intensive Care Med 2003; 29:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/124\">",
"      Harris OA, Colford JM Jr, Good MC, Matz PG. The role of hypothermia in the management of severe brain injury: a meta-analysis. Arch Neurol 2002; 59:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/125\">",
"      Clifton GL, Valadka A, Zygun D, et al. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. Lancet Neurol 2011; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/126\">",
"      Hutchison JS, Ward RE, Lacroix J, et al. Hypothermia therapy after traumatic brain injury in children. N Engl J Med 2008; 358:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/127\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. III. Prophylactic hypothermia. J Neurotrauma 2007; 24 Suppl 1:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/128\">",
"      Adelson PD. Hypothermia following pediatric traumatic brain injury. J Neurotrauma 2009; 26:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/129\">",
"      Rovlias A, Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery 2000; 46:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/130\">",
"      Jeremitsky E, Omert LA, Dunham CM, et al. The impact of hyperglycemia on patients with severe brain injury. J Trauma 2005; 58:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/131\">",
"      Lam AM, Winn HR, Cullen BF, Sundling N. Hyperglycemia and neurological outcome in patients with head injury. J Neurosurg 1991; 75:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/132\">",
"      Oddo M, Schmidt JM, Carrera E, et al. Impact of tight glycemic control on cerebral glucose metabolism after severe brain injury: a microdialysis study. Crit Care Med 2008; 36:3233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/133\">",
"      Harhangi BS, Kompanje EJ, Leebeek FW, Maas AI. Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien) 2008; 150:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/134\">",
"      Allard CB, Scarpelini S, Rhind SG, et al. Abnormal coagulation tests are associated with progression of traumatic intracranial hemorrhage. J Trauma 2009; 67:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/135\">",
"      Wafaisade A, Lefering R, Tjardes T, et al. Acute coagulopathy in isolated blunt traumatic brain injury. Neurocrit Care 2010; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/136\">",
"      Stein SC, Young GS, Talucci RC, et al. Delayed brain injury after head trauma: significance of coagulopathy. Neurosurgery 1992; 30:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/137\">",
"      Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/138\">",
"      Zehtabchi S, Soghoian S, Liu Y, et al. The association of coagulopathy and traumatic brain injury in patients with isolated head injury. Resuscitation 2008; 76:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/139\">",
"      Perel P, Roberts I, Shakur H, et al. Haemostatic drugs for traumatic brain injury. Cochrane Database Syst Rev 2010; :CD007877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/140\">",
"      Narayan RK, Maas AI, Marshall LF, et al. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery 2008; 62:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/141\">",
"      Winter JP, Plummer D, Bottini A, et al. Early fresh frozen plasma prophylaxis of abnormal coagulation parameters in the severely head-injured patient is not effective. Ann Emerg Med 1989; 18:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/142\">",
"      Etemadrezaie H, Baharvahdat H, Shariati Z, et al. The effect of fresh frozen plasma in severe closed head injury. Clin Neurol Neurosurg 2007; 109:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/143\">",
"      Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004; 364:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/144\">",
"      Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005; 365:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/145\">",
"      Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007; 49:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/146\">",
"      Ma J, Huang S, Qin S, You C. Progesterone for acute traumatic brain injury. Cochrane Database Syst Rev 2012; 10:CD008409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/147\">",
"      Arango MF, Bainbridge D. Magnesium for acute traumatic brain injury. Cochrane Database Syst Rev 2008; :CD005400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/148\">",
"      Zafonte R, Friedewald WT, Lee SM, et al. The citicoline brain injury treatment (COBRIT) trial: design and methods. J Neurotrauma 2009; 26:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/149\">",
"      Mazzeo AT, Brophy GM, Gilman CB, et al. Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial. J Neurotrauma 2009; 26:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/150\">",
"      Xiong Y, Mahmood A, Chopp M. Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs 2009; 14:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/151\">",
"      Talving P, Lustenberger T, Kobayashi L, et al. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg 2010; 251:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/152\">",
"      Velmahos GC. Erythropoiesis and the mystery of an unexplained survival benefit. Ann Surg 2010; 251:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/153\">",
"      Cruz J. The first decade of continuous monitoring of jugular bulb oxyhemoglobinsaturation: management strategies and clinical outcome. Crit Care Med 1998; 26:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/154\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. X. Brain oxygen monitoring and thresholds. J Neurotrauma 2007; 24 Suppl 1:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/155\">",
"      Maloney-Wilensky E, Gracias V, Itkin A, et al. Brain tissue oxygen and outcome after severe traumatic brain injury: a systematic review. Crit Care Med 2009; 37:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/156\">",
"      Stiefel MF, Spiotta A, Gracias VH, et al. Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring. J Neurosurg 2005; 103:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/157\">",
"      Goodman JC, Robertson CS. Microdialysis: is it ready for prime time? Curr Opin Crit Care 2009; 15:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/158\">",
"      Jiang JY, Gao GY, Li WP, et al. Early indicators of prognosis in 846 cases of severe traumatic brain injury. J Neurotrauma 2002; 19:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/159\">",
"      Lingsma HF, Roozenbeek B, Steyerberg EW, et al. Early prognosis in traumatic brain injury: from prophecies to predictions. Lancet Neurol 2010; 9:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/160\">",
"      Schn&uuml;riger B, Inaba K, Abdelsayed GA, et al. The impact of platelets on the progression of traumatic intracranial hemorrhage. J Trauma 2010; 68:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/161\">",
"      Calvi MR, Rosa CM, Beretta L, et al. Early prognosis after severe traumatic brain injury with minor or absent computed tomography scan lesions. J Trauma 2011; 70:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/162\">",
"      Timmons SD, Bee T, Webb S, et al. Using the abbreviated injury severity and Glasgow Coma Scale scores to predict 2-week mortality after traumatic brain injury. J Trauma 2011; 71:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/163\">",
"      McMillan TM, Teasdale GM, Weir CJ, Stewart E. Death after head injury: the 13 year outcome of a case control study. J Neurol Neurosurg Psychiatry 2011; 82:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/164\">",
"      Rosner MJ, Rosner SD, Johnson AH. Cerebral perfusion pressure: management protocol and clinical results. J Neurosurg 1995; 83:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/165\">",
"      Levin HS, Saydjari C, Eisenberg HM, et al. Vegetative state after closed-head injury. A Traumatic Coma Data Bank Report. Arch Neurol 1991; 48:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/166\">",
"      Xu W, Jiang G, Chen Y, et al. Prediction of minimally conscious state with somatosensory evoked potentials in long-term unconscious patients after traumatic brain injury. J Trauma Acute Care Surg 2012; 72:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/2/35882/abstract/167\">",
"      Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 2012; 366:819.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4826 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35882=[""].join("\n");
var outline_f35_2_35882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25687318\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prehospital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Emergency department",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Subdural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Depressed skull fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Decompressive craniectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INTENSIVE CARE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General medical care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Diagnosis and initial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Osmotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hyperventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cerebral perfusion pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Temperature management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Induced hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Glucose management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7527255\">",
"      Hemostatic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Neuroprotective treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ADVANCED NEUROMONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4826\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4826|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/0/22530\" title=\"diagnostic image 1A\">",
"      CT traumatic SDH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/9/29843\" title=\"diagnostic image 1B\">",
"      CT Diffuse axonal injury after TBI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/4/12354\" title=\"diagnostic image 1C\">",
"      CT bifrontal cerebral contusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/10/41123\" title=\"diagnostic image 1D\">",
"      CT traumatic EDH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4826|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/61/28625\" title=\"figure 1\">",
"      External ventricular device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4826|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/569?source=related_link\">",
"      Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11784?source=related_link\">",
"      Emergency airway management in the patient with elevated ICP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19112?source=related_link\">",
"      Intracranial epidural hematoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4935?source=related_link\">",
"      Post-traumatic seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3481?source=related_link\">",
"      Skull fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13704?source=related_link\">",
"      Skull fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43767?source=related_link\">",
"      Subdural hematoma in adults: Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39062?source=related_link\">",
"      Traumatic brain injury: Epidemiology, classification, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_2_35883="Clinical characteristics of PMDs";
var content_f35_2_35883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical characteristics of psychogenic movement disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abrupt onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of a precipitating event",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fast progression to maximum symptom severity and disability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Movement abnormality that is incongruent with organic disease (eg, bizarre, multiple or difficult to classify)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inconsistency over time with variable amplitude, frequency, or distribution of the movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to trigger or relieve the abnormal movements with unusual or nonphysiologic intervention (eg, trigger points on the body, application of a tuning fork)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased movement of the affected body part with distraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased movement of the affected body part during observation or examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Entrainment of movement (eg, tremor) to the frequency of repetitive movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coactivation sign of antagonist muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deliberate slowness of movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Association with false weakness, sensory loss, and pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional disability out of proportion to exam findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unresponsiveness to drugs for organic movement disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Response to placebo drugs and suggestion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35883=[""].join("\n");
var outline_f35_2_35883=null;
var title_f35_2_35884="Pediatric ambulance equipment for advanced life support";
var content_f35_2_35884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric equipment and supplies for advanced life support (ALS) ambulances in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ALS ambulances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Required*&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Airway and ventilation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Laryngoscope handle, extra batteries and bulbs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Laryngoscope blades: straight (Miller) sizes 0-4; curved (MacIntosh) sizes 2-4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Endotracheal tubes: uncuffed sizes 2.5-5.5 mm; cuffed 6-8 mm (2 of each size and type)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Meconium aspirator adaptor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       10-mL non-Luerlock syringes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stylettes for endotracheal tubes: adult and pediatric",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Magill (Rovenstein) forceps, adult and pediatric",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Lubricating jelly (water soluble)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       End-tidal CO",
"       <sub>",
"        2",
"       </sub>",
"       detector (adult and pediatric colorimetric or quantitative capnometry)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Monitoring and defibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Portable, battery-operated monitor/defibrillator with tape write-out/recorder, defibrillator pads, quick-look paddles or electrodes or hands-free patches, ECG leads, adult and pediatric chest attachment electrodes, adult and pediatric paddles",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Transcutaneous cardiac pacemaker with pediatric pads and cables (standalone or integrated into monitor/defibrillator)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Optional advanced equipment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Respirator (volume-cycled, on/off operation, 100 percent oxygen, 40-50 psi pressure (child/infant capabilities))",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pediatric blood sample tubes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nasogastric tubes, pediatric feeding tube sizes 5 F and 8 F, sump tube sizes 8 F-16 F",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pediatric laryngoscope handles",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Size 1 curved (MacIntosh) laryngoscope blades",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3.5 to 5.5 mm cuffed endotracheal tubes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Needle cricothyrotomy capability",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CO",
"     <sub>",
"      2",
"     </sub>",
"     : carbon dioxide; ECG: electrocardiogram; psi: pounds per square inch; F: French.",
"     <br>",
"      * In addition to the standard equipment and supplies as determined by state and local regulations.",
"      <br>",
"       &bull; In addition to items for basic life support ambulances.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Policy statement--Equipment for ambulances. American College of Surgeons Committee on Trauma, American College of Emergency Physicians, National Association of EMS Physicians, Pediatric Equipment Guidelines Committee - Emergency Medical Services for Children (EMSC) Partnership for Children Stakeholder Group, American Academy of Pediatrics. Pediatrics 2009; 124:e166.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35884=[""].join("\n");
var outline_f35_2_35884=null;
var title_f35_2_35885="Maternal analyte changes associated w adverse pregnancy outcome";
var content_f35_2_35885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66599%7EOBGYN%2F54068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66599%7EOBGYN%2F54068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Associations between maternal serum markers for aneuploidy and adverse outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preeclampsia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Birthweight less than 10th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preterm birth",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fetal death at or before 24 wk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fetal death after 24 wk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAPP-A (&lt;0.42 MoM)",
"       </td>",
"       <td>",
"        +/++",
"       </td>",
"       <td>",
"        ++/+++",
"       </td>",
"       <td>",
"        <p>",
"         + (32 wk or less)",
"        </p>",
"        <p>",
"         ++ (less than 34 wk)",
"        </p>",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++/+++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Free &beta;-hCG (&lt;0.21 MoM)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -/++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AFP (&gt;2.0 MoM)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        <p>",
"         - (32 wk or less)",
"        </p>",
"        <p>",
"         + (37 wk)",
"        </p>",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -/+++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        hCG (&gt;2.0 MoM)*",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        <p>",
"         - (greater than 24 wk)",
"        </p>",
"        <p>",
"         +++ (greater than 500 g)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        uE3 (&lt;0.5 MoM)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibin A (&gt;2.0 MoM)",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: adjusted odds ratio (OR) greater than 1.0; ++: adjusted OR greater than 2.0; +++: adjusted OR greater than 3.0; -: adjusted OR not significant (P &ge;.05); PAPPA: pregnancy-associated plasma protein-A; MoM: multiples of the median; AFP: alpha-fetoprotein; uE3: unconjugated estriol.",
"     <br>",
"      * Although an isolated human chorionic gonadotropin (hCG) was not significantly associated with the adverse outcomes, a hCG level greater than 2.0 MoM was significantly associated with preeclampsia, birth weight less than the 10th percentile for gestational age, preterm birth 32 weeks or less, and early and late fetal loss.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dugoff L. Society for Maternal-Fetal Medicine: First- and Second-Trimester Maternal Serum Markers for Aneuploidy and Adverse Obstetric Outcomes. Obstet Gynecol 2010; 115:1052. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Association between selected individual and combinations of markers and adverse pregnancy outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Marker(s)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preterm birth at 32 wk or less",
"      </td>",
"      <td class=\"subtitle1\">",
"       Birth weight 5th percentile or less",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preeclampsia",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fetal loss at 24 wk or less",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fetal loss at greater than 24 wk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AFP",
"      </td>",
"      <td>",
"       1.76 (0.81-3.84)",
"      </td>",
"      <td>",
"       2.49 (1.82-3.4)",
"      </td>",
"      <td>",
"       0.83 (0.44-1.56)",
"      </td>",
"      <td>",
"       3.63 (1.81-7.27)",
"      </td>",
"      <td>",
"       0.70 (0.10-5.03)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       hCG",
"      </td>",
"      <td>",
"       0.83 (0.43-1.58)",
"      </td>",
"      <td>",
"       0.99 (0.76-1.27)",
"      </td>",
"      <td>",
"       1.19 (0.88-1.61)",
"      </td>",
"      <td>",
"       1.54 (0.85-2.81)",
"      </td>",
"      <td>",
"       1.38 (0.63-3.01)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       uE3",
"      </td>",
"      <td>",
"       1.68 (0.61-4.64)",
"      </td>",
"      <td>",
"       1.97 (1.28-3.04)",
"      </td>",
"      <td>",
"       1.70 (0.92-3.15)",
"      </td>",
"      <td>",
"       7.00 (3.70-13.24)",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inhibin A",
"      </td>",
"      <td>",
"       2.38 (1.44-3.95)",
"      </td>",
"      <td>",
"       1.68 (1.29-2.18)",
"      </td>",
"      <td>",
"       2.39 (1.75-3.26)",
"      </td>",
"      <td>",
"       0.98 (0.36-2.66)",
"      </td>",
"      <td>",
"       2.41 (1.04-5.56)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AFP + inhibin A",
"      </td>",
"      <td>",
"       20.37 (9.38-44.22)",
"      </td>",
"      <td>",
"       4.28 (2.20-8.32)",
"      </td>",
"      <td>",
"       4.26 (1.91-9.51)",
"      </td>",
"      <td>",
"       18.01 (7.51-43.19)",
"      </td>",
"      <td>",
"       9.2 (2.2-38.43)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       hCG + inhibin A",
"      </td>",
"      <td>",
"       3.28 (1.97-5.46)",
"      </td>",
"      <td>",
"       2.05 (1.52-2.77)",
"      </td>",
"      <td>",
"       3.73 (2.73-5.08)",
"      </td>",
"      <td>",
"       2.03 (0.88-4.65)",
"      </td>",
"      <td>",
"       4.27 (1.95-9.32)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AFP + hCG + inhibin A",
"      </td>",
"      <td>",
"       5.51 (2.23-13.62)",
"      </td>",
"      <td>",
"       6.50 (3.89-10.89)",
"      </td>",
"      <td>",
"       7.04 (3.90-12.73)",
"      </td>",
"      <td>",
"       16.34 (7.56-35.33)",
"      </td>",
"      <td>",
"       6.93 (1.66-28.9)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are expressed as adjusted odds ratio (95% confidence interval).",
"    <div class=\"footnotes\">",
"     AFP: alpha-fetoprotein; hCG: human chorionic gonadotropin; uE3: unconjugated estriol; NA: not applicable.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dugoff L. Society for Maternal-Fetal Medicine. First- and Second-Trimester Maternal Serum Markers for Aneuploidy and Adverse Obstetric Outcomes. Obstet Gynecol 2010; 115:1052. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35885=[""].join("\n");
var outline_f35_2_35885=null;
var title_f35_2_35886="Diaphragm fitting kit";
var content_f35_2_35886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaphragm fitting kit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35886=[""].join("\n");
var outline_f35_2_35886=null;
var title_f35_2_35887="L monocytogenes tumbling motility";
var content_f35_2_35887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/ID/61238/lmonocyt_conv.mp4?title=L+monocytogenes+tumbling+motility\" style=\"width:432px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tumbling motility of Listeria monocytogenes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hanging drop slide of an overnight brain heart infusion broth inoculated with Listeria monocytogenes. In the video, the bacteria rotate slowly in and out of focus around a central axis; a characteristic and specific movement pattern referred to as \"tumbling motility\" (magnification x400).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chau TTH, Campbell JI, Schultsz C, et al. Three Adult Cases of Listeria monocytogenes Meningitis in Vietnam. PLoS Med 2010; 7:e1000306. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_2_35887=[""].join("\n");
var outline_f35_2_35887=null;
